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Human Umbilical Cord Blood Cells Migration To Stroke CNS Tissue Extracts 
And The Potential Cytokines And Chemokines Involved 
 
Mary B. Newman 
ABSTRACT 
  Human umbilical cord blood (HUCB) cells consist of a heterogeneous 
population of cells, rich in hematopoietic stem and progenitor cells.  These cells have 
been used in the treatment of various nonmalignant and malignant hematopoietic 
diseases.  With in the last few years HUCB cells have been used in pre-clinical animal 
models of brain and spinal cord injuries, in which functional recovery has been shown. 
The properties of cord blood cells that could be important in cell transplantation (repair or 
replacement) of CNS injury or disease are currently being evaluated.  The major focus of 
this study was to determine whether HUCB cells would migrate to ischemic tissue 
extracts.  In addition, factors that may be inducing the cells to migrate were examined by 
identifying the cytokines or chemokines present in the ischemic tissue extracts.  The 
secondary focus was to establish whether cultured HUCB cells are releasing cytokines 
and chemokines (in vitro) in response to their environment.  The results of these studies 
showed that HUCB cells migrate to ischemic tissue in a time dependent manner.  In 
which there is a 48 to 72 hour window of opportunity for the delivery of HUCB cells to 
the ischemic brain.  In addition, the cord blood cells were shown to release cytokines and 
chemokines that may be aiding in the behavioral recovery seen in the transplantation  
 
vii 
 studies.  The results from this study are promising in that the current 3-hour therapeutic 
window for the treatment of stroke victims, using approved anticoagulant treatment, may 
be extended with the use of cord blood cell therapy with the peak at 48 hours. 
viii 
  
 
Chapter 1 
  
1.0 Umbilical Cord Blood (HUCB) Cells in the Repair of Damage in the CNS 
 
1.1 Introduction 
Numerous CNS diseases are characterized by the deterioration of cognitive and 
motor functions, frequently leading to prolonged periods of increasing incapacity.  
Among the most problematic and prevalent neurological disorders are those associated 
with the loss of CNS cells populations, such as Alzheimer’s (AD), Parkinson’s (PD), 
Huntington’s disease (HD), amyotropic lateral scelerosis (ALS), and stroke.  While 
advances in molecular biology, genetic engineering, proteomics, and genomics will 
hopefully produce compounds with enormous treatment potential in the future, currently 
there are no available means of altering the pattern, rate of cell loss, or function in 
diseased or injured CNS once damage has occurred. 
 For several decades, researchers and clinicians have been exploring the potential 
of cellular treatment for diseases, disorders, and injuries of the CNS.  Fetal neural tissue 
was initially grafted into the brain in order to study its development and regenerative 
capacity.  These studies quickly revealed the therapeutic potential of tissue grafting in 
animal models of neurological disorders, which eventually led to pre-clinical and then 
clinical trials.  The outcomes of clinical transplantation studies were generally positive 
enough to warrant further investigation.  However, the lack of significant improvement 
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 reported in the older population or late stage of disease in patients with Parkinson’s 
disease has brought some doubt and uncertainty to the future direction of the neural 
transplantation field (Newman et al 2003, Sanberg et al 2002) 
In addition, societal, legal, and ethical issues, along with the limited availability 
of tissue, complicate the use of fetal tissue.  These factors have not only pushed 
investigators to look for alternative sources of cells, but also alternative ways in which 
cells may be utilized in cellular therapies.  This is supported by the growing consensus 
that stem cells are obtainable from several sources and can be epigenetically expanded or 
genetically perpetuated to develop, if needed, into specific cellular phenotypes or to 
deliver needed substrates/factors from genetically engineered cells.  One of the most 
promising sources for human stem cells is those cells from hematopoietic origin, which 
include HUCB, adult peripheral blood, and bone marrow.  Each has their own sets of 
distinct advantages and disadvantages and a comprehensive review of each source is 
beyond the scope of this dissertation.  This chapter will focus on the utilization of HUCB 
cells as a potential source for cellular therapies, the clinical and pre-clinical studies that 
have been preformed, and a general description of research undertaken for this 
dissertation. 
Stem cells derived from hematopoietic sources, such as HUCB, are an emerging 
and relatively young area of research that may provide the opportunity to further our 
understanding of the extent and limitations in the use of stem cells in cellular therapy 
field.   
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 1.2 Brief History of Stem Cells 
 Most stem cell biologists would agree that Artur Pappenheim (1870 – 1916) was 
the first to propose the concept of a common ancestral stem cell (Lajtha 1980), 1980).  
Till and McCulloch (1961) were the first to demonstrate the ability of transplanted bone 
marrow cells to form colony-forming units (CFU) on the spleen of lethally irradiated 
mice in vitro.  Their initial studies, measured the proliferation potential of bone marrow 
cell colonies, and led to the developing hypothesis of hematopoietic stem cells (Potten 
1983, Till & McCulloch 1961).  Since then much confusion has occurred in the meaning 
and usage of the words “stem, progenitor, and precursor cells.”   
In an attempt to unify terminology in this field, a workshop in 1978 comprised 
mostly of hematologists (Lajtha 1979a, Lajtha 1979b, Schofield & Lajtha 1983), defined 
stem cells as “cells with extensive self-maintaining (self-renewal capacity), extending 
throughout the whole (or most) of the life-span of the organism.  Differentiation potential 
is a property of some types of stem cells but is not an essential feature of stem-ness.”  
Differentiation has been defined as “cells becoming specialized for particular functions” 
(Lackie & Dow, 1999) and as “the change in genetic expression patterns” (Lajtha 1979a).  
Therefore, any cell that replicates its own numbers throughout most of the organism’s life 
is considered a stem cell, regardless of whether the cell differentiates further.  As Lajtha 
(Lajtha 1979b) has pointed out, “every cell in the body except for the zygote is already 
differentiated,” the question is whether a cell is capable of further differentiation (Lajtha 
1979b).  More recently, however, other scientists, mostly in the neuroscience and 
transplantation field, have defined a stem cell as – an undifferentiated cell that is capable 
of self-renewal, proliferation, and can asymmetrically divide to generate differentiated 
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 cells or multipotent cells (Rao & Mattson, 2001; Shihabuddin, et al. 1999; Gage, 2000).  
At this time there seems to be a consensus regarding the terminology stem cells, although 
there has been no formal establishment of a nomenclature.  Table 1.1 presents a 
hierarchical listing along with defined terminology of stem cells, which has been 
incorporated from several scientific publications. Please refer to the following papers for 
their discussion of this topic: (Blau et al 2001, Marshak et al 2001, National Research 
Council (U.S.). Committee on the Biological and Biomedical Applications of Stem Cell 
Research., Rao 2001a, Rao & Mattson 2001, Rao 2001b).  
Totipotent stem cells are of interest due to their ability to generate any cell type 
from both ectodermal and extraectodermal tissue.  Pluripotent stem cells can give rise to 
cells derived from the three embryonic germ layers, however, they are more restricted, 
produce committed progenitor and precursor stem cells of more than one lineage or cell 
type, and can self-renew.  Cell lineage can be described as the embryonic origins of 
specific cells, which can be recorded through fate maps that trace the cell(s) embryonic 
origin through developmental stages.  Accordingly, a stem cell that is more ancestral or 
primitive (higher in the hierarchy) is of greater interest due to the cell’s ability to generate 
progenitors of more than one lineage.  The progenitor and precursor cells are more 
limited (more restricted) than stem cells in their ability to give rise to cells of a different 
lineage.   
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 Table 1.1: Description of Stem Cells       
Primitive Stem Cells 
Totipotent – early blastula stage cells, giving rise to both ectodermal 
and extraectodermal tissue.   
 
Stem Cells 
A cell that is capable of proliferation, self-renewal, self-maintaining 
during the life of the organism is a stem cell.  The cell may or may 
not produce cells that are further differentiated.  
 
  Ancestral Cell – stem cells that yield further differentiated 
descendants. 
 
Pluripotent Stem Cells – These cells originate from the inner cell 
mass after development of the blastula, they give rise to cells from 
the three embryonic germ layers (mesoderm, endoderm and 
ectoderm).  However, they cannot give rise to the tissue of the 
placenta (this is restricted to cells from the trophectoderm).  They 
can differentiate into germinal and somatic tissues.  
 
Multipotent, Bipotent and Unipotent – these are used to describe 
stem cells that are further differentiated daughter cells of 
pluripotent or totipotent stem cells.  They may produce daughter 
cells that are further differentiated.  However, they are restricted in 
the ability to give rise to other cells of different lineages.   
 
Progenitor/Precursor Cells    
These are the progeny of stem cells, and have a much more 
restricted differentiation potential with limited self-renewal 
capacity, and a limited lifespan.  These cells cycle more than stem 
cells and provide the necessary cells for self-maintenance of the 
organism, thus conserving the stem cell.  
            
Table 1.1 Presents an interpretation of the hierarchy and increased 
complex terminology of stem cells.  The definitions are a compilation 
from several sources as referenced in the paper.    
 
Both the progenitor and precursor cells (also referred to as transit amplifying 
cells) are the progeny of more ancestral stem cells and seem to be responsible for the 
ongoing regeneration of the given tissue in which they reside; allowing the more 
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 primitive stem cells to proliferate only as necessary (Marshak et al 2001).  This concept is 
in agreement with the slow cycling observed in more primitive stem cells, which has 
been proposed as a way to protect the integrity of the genome (Cairns 1975, Potten 1983).  
Thus, the fewer cell cycles, the less chance there is of disrupting or damaging the 
genome.   
 The endogenous factors that trigger proliferation and differentiation of stem cells 
and their progeny are just beginning to be resolved.  The proliferation, expansion, and 
differentiation of stem cells are regulated through intrinsic cellular factors, extrinsic 
cellular factors (cytokines/growth factors, cell adhesion molecules), and cell-to-cell 
interaction (Rao & Mattson 2001).  For example, embryonic stem cells can be maintained 
in vitro in the presence of Leukemia Inhibitory Factor (LIF) and these cells will produce 
neural stem cells when supplemented with fibroblast growth factor (FGF) in culture 
(Tropepe et al 2001).  Both epidermal growth factor (EGF) and basic fibroblast growth 
factors (FGF2) will keep neural stem cells in a proliferative state (Gritti et al 1999), while 
brain derived neurotrophic factor (BDNF) will direct neuronal progenitors to 
differentiation (Eaton & Whittemore 1996).  Some stem cells have been reported to 
transdifferentiate; that is to give rise or transit to a cell with properties distinct from the 
germinal layer in which they originated.  Kondo and Raff (2000) have shown that 
oligodendrocyte progenitor cells may transdifferentiate to pluripotent stem cells and give 
rise to neurons(Kondo & Raff 2000).  However, caution should be employed when 
determining the ability of a cell to transdifferentiate.  Progenitor cells that were obtained 
from muscle and thought to be of muscle origin were reported to transdifferentiate into 
hematopoietic stem cells.  Upon further investigation, these stem cells were, in fact, 
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 determined to be hematopoietic stem cells residing within the muscle (Ogawa et al 2002).  
While it is possible to direct the differentiation of pluripotent stem cells and lineage 
restricted progenitor cells in vitro, we are only at the initial stages of learning how to 
direct stem cells to phenotypes that might be useful in vivo. 
 
1.3 Advantages of HUCB Cells 
Many fundamental observations have already been made in the use of cord blood 
cells as transplantable cells for treating CNS diseases.  Those observations are discussed 
here.  
1.3.1 Easily Obtainable Source of Cells 
HUCB is a well-established, reliable source of a heterogeneous population of 
cells, which is known to be rich in hematopoietic stem and progenitor cells (Broxmeyer 
1996, Mayani & Lansdorp 1998).  Additionally, millions of healthy babies are born each 
year leading to virtually an unlimited supply of HUCB cells that can be easily preserved 
and available for transplantation at any time.  Cord blood is easily obtained and routinely 
collected without jeopardizing the mother or infant (National Center For Farmworkers 
2002).  Cord blood can be collected either in utero or ex utero.  Typically, cord blood is 
collected after the placenta has been delivered (ex utero - which does not endanger 
mother or infant) in a closed system to prevent contamination, which utilizes either 
placental collection bags or blood collection bags that contain the anticoagulants.  The 
placenta is suspended in a specially designed scaffold enabling the cord to hang down 
and causing enlargement of the cord.  This permits easier access in which to cannulate 
the cord vein and allow the blood to drain.  Standard procedures are used to process and 
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 test the isolated cord blood to ensure the absence of infectious agents such as HIV and 
hepatitis prior to cryopreservation.  In addition, cord blood cells are available from every 
ethnic group for human leukocyte antigen (HLA) matching.  The cells that are isolated 
from the cord blood have the advantage of being immunologically immature (discussed 
below) and thus are less likely to rejected by the host..  Obviously, the ethical issues 
associated with using cells or tissues from embryos or aborted fetuses are obviated, 
removing the arguments that a potential life is being sacrificed for the advancement of 
science or that the use of aborted fetuses influences or justifies the decision to have an 
abortion.  
1.3.2 Abundant Source of Cryopreservable Cells 
The yield of hematopoietic stem cells is relatively high with a greater potential 
for proliferation and expansion when compared to those of adult bone marrow (Cardoso 
et al 1993a, Cardoso et al 1993b, Hows et al 1992).  For example, a higher percentage of 
cluster differentiation (CD)34+ CD38- cells are present in HUCB; 4% fraction when 
compared 1% bone marrow (Broxmeyer et al 1992b, Cardoso et al 1993b, Metcalf 1984).  
In addition, cord blood contains CD133 positive cells, which are a subpopulation of 
CD34 cells and are believed to be more primitive stem cells (Miraglia et al 1997, Potgens 
et al 2001, Yin et al 1997) (see section – on phenotypes for further discussion).  The 
advantages of a high yield of stem and progenitor cells dovetails nicely with the ability to 
cryopreserve cord blood cells for indefinite period, which is an essential prerequisite for 
any cell-based therapy.  With proper handling and processing cryopreservation does not 
materially affect the viability of the stem or progenitor cells obtained from HUCB.  Cells 
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 from cord blood frozen maintain their viability and proliferation capacities for as long as 
15 years and are no different than HUCB cells stored for shorter periods (Broxmeyer & 
Cooper 1997, Broxmeyer et al 2003).  For example, cells that were magnetically 
separated with CD34 antibody and cryopreserved for 15 years were infused into 
irradiated NOD/SCID mice.  After 11-13 weeks in vivo the cells expressed multi-lineage 
phenotypes that were comparable to those obtained using freshly harvested cord blood 
(Broxmeyer et al 2003).  More importantly, cryopreserved cord blood stored up to 4 
years has been transplanted successfully in allogeneic sibling that had malignant or non-
malignant diseases (Broxmeyer 1998b, Wagner et al 1992).   
Cryopreservation may actually confer certain advantages, in gene therapy, 
relative to fresh, non-cryopreserved cord blood.  Cord blood cells that have been 
cryopreserved transduce retroviral vectors more easily than fresh cells, and this has been 
suggested to be the result of higher expression of amphotropic retrovirus receptor mRNA 
in the cryopreserved cord blood cells (Orlic et al 1999a, Orlic et al 1999b).  The easy 
transduction of retroviral vectors and the high expression of amphotropic retrovirus 
receptor on HUCB cells may suggest a role for these cells in gene therapy, especially 
since, amphotropic retrovirus receptors are the most widely used receptors for the 
transduction of gene vectors currently.  This area is further discussed in section “HUCB 
Stem Cells for Gene Therapy.”  
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 1.3.3 Low Incidence of GvHD Following Transplantation of Cord Blood Cells 
and Their Immune Immaturity  
In children that were transplanted with HUCB cells from related or unrelated 
donor with one HLA-mismatch there was a  low incidence of graft-vs-host disease 
(GvHD) (Gluckman 2001, Rocha et al 2001, Rocha et al 2000; Wagner et al 1995).  This 
suggests that the host antigen-presenting cells did not recognize these transplanted cells 
as foreign.  The immaturity of cord blood cells has been postulated as the reason for this 
low rejection rate.  Several converging lines of evidence support this notion.  One way to 
study this area of immune immaturity is to compare the phenotypes and functionality of 
T-lymphocytes in cord blood to that of mature T-cells such as those from adult blood (for 
review on this subject see – Fallen & Cohen 2000).  Most T cells from cord blood 
express CD45RA (naïve isoform) with a few expressing CD45RO (mature - memory 
isoform), whereas in adult blood the opposite of this is true with few CD45RA and more 
CD45RO cells (Beck & Lam-Po-Tang 1994, Han et al 1995).  Also in cord blood there 
are fewer T cells that express CD29 compared to adult blood T cells (Rabian-Herzog et 
al 1993).  In the adult, CD29 recognizes T cells (CD4 positive memory cells) that have 
been stimulated by specific antigen, therefore the lack of CD29 expression in cord blood 
T cells is further evidence of their naïve state.  In addition, the expression of the receptor 
α subunit for IL –2 (CD25), a potent cytokine that acts as a major T cell growth factor, is 
markedly lower in cord blood cells than in adult blood cells (Cohen et al 1999).  
Moreover, in cord blood the functional response of T cells is less than those cells in the 
adult blood.  For instance, approximately 30% of CD45RA T cells from neonates 
produce CD40 ligand (CD40L) whereas over 80% of T cells in adult blood have been 
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 shown to produce this ligand (Fallen & Cohen 2000, Nonoyama et al 1995).  CD40L 
plays a role in the maturation of B cells and it has been proposed that the lack of CD40L 
production in T cells contributes to the immaturity of B cells in cord blood.  This 
coincides with B cell production of IgG or IgA, which is less in the blood of newborns 
compared to adult blood (Miyawaki et al 1981, Nagaoki et al 1981).  Furthermore, the 
production of certain cytokines, such as IL-2, IL-3, and IFN, is less in T cells from cord 
blood than adult blood (for review see –  Fallen, 2000).   
A second line of evidence is based on telomeric analysis of HUCB cells.  Cellular 
division is associated with a sequential loss of telomeric DNA leading to cellular 
senescence.  Adult bone marrow cells have inherently shorter telomeres than cord blood 
cells, providing circumstantial evidence that HUCB cells are immature(Vaziri et al 
1994).     
Together this evidence strongly supports the proposition that HUCB cells are 
immune-immature and further suggests the immune cells within cord blood are 
functionally and phenotypically at an early stage of development.  If additional studies 
confirm that HUCB cells are indeed in an immature state at the time of delivery and 
shortly thereafter, this raises the clinically important possibility that immunosuppressive 
therapy may not be necessary at the time of transplantation.  The ability to avoid 
immunosuppression is especially important for children who are victims of stunted 
growth, when have increased risk of malignancy resulting from systemic 
immunosuppressant therapy. 
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 1.3.4 HUCB Cells Have Been Safely Transplanted Clinically for Over 15 
Years 
Systemic administration of HUCB cells has a long standing and successful 
history in the hematopoietic field and is commonly used to treat various nonmalignant 
and malignant hematopoietic diseases (for review see - Broxmeyer 2000, Lu et al 1996).  
The first documented HUCB transplant with an HLA-matched sibling was performed in 
1988 on a child with Fanconi’s anemia.  The procedure was well tolerated and, at last 
report, the patient had survived for more than nine years without disease reoccurrence 
(Broxmeyer 2000, Gluckman et al 1989).   Concurrent pre-clinical studies demonstrated 
that the bone marrow of lethally irradiated adult mice could be fully 
rescued/reconstituted by injections of cord blood from pre-term and term deliveries 
(Broxmeyer 1998a, Broxmeyer et al 1991).  Since these initial reports, over 850 cord 
blood transplants have been performed in children (NMDP, 2003) using either complete 
or partial HLA-antigen matches for the treatment of nonmalignant and malignant 
hematopoietic diseases (for reviews see – Broxmeyer 1998a, Lu et al 1996).   
HUCB has also been successfully transplanted into adult recipients although the 
number of transplants are fewer than those performed on children (Gluckman et al 1997, 
Laughlin et al 2001).  Fewer adult transplants have been performed because of the open 
question concerning the appropriate “dosage” of HUCB cells.  It is unknown whether a 
single collection or sample of cord blood contains enough stem cells to repopulate the 
adult hematopoietic system.  Despite the need for continued clinical evaluation to 
address this issue, HUCB cells from a single donor have been successfully used.  
Interestingly, the number of cord blood cells infused in these studies has often been less 
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 than the number of bone marrow cells typically used (Gluckman et al 1999a, Gluckman 
et al 1999b) further supporting the supposition that the number of hematopoietic stem 
cells residing in cord blood is sufficient for improved clinical outcome.  These 
suppositions from the clinical data are supported by quantitative in vitro evidence in 
which the number of myeloid progenitor cells supplemented with steel factor (SLF) and 
hematopoietic colony-stimulating factors (CSFs) were analyzed. The result suggested 
that a single collection of cord blood contains a sufficient number of cells for 
engraftment and repopulation of the adult hematopoietic system  (for review see - 
Broxmeyer et al 1992a).   
 
1.4 Phenotyping of HUCB Cells 
Careful and accurate phenotyping of cells within a heterogeneous substrate such 
as cord blood is essential for full realization of the clinical potential.  Clonogenic assay, 
flow cytometry, and the expression of CD antigens coupled with self-renewal 
proliferation assays have historically been used to delineate hematopoietic stem and 
progenitor cells from the other cellular components of cord blood.  Clonogenic assays 
have identified several colony-forming units, such as, erythroid burst forming units 
(BFUe), granulocyte-macrophage colony-forming cells (CFU-GM), and granulocyte-
erythroid-macrophage-megakaryocyte colony forming units (CFU-GEMM) (Broxmeyer 
& Carow 1993, Broxmeyer et al 1989).   Phenotypic markers that recognize cell 
surface components, such as CD34 (a type I transmembrane glycophosphoprotein), are 
routinely used to identify and sort cells.  CD34 is believed to identify hematopoietic stem 
cells, but the expression of this protein alone does not reliably distinguish hematopoietic 
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 stem cells from progenitor cells.  For example, the heterogeneous population of cells in 
cord blood consist of several lineage committed cells that express CD34: myeloid lineage 
cells that consist of mononuclear phagocytes and granulocytes co-express CD34 and 
CD33 (marker for myeloid progenitor cell); erythroid lineage cells co-express CD34 and 
CD71 ( a proliferating cell marker); lymphoid lineage cells can co-express CD34 with 
either CD19 (B cells) or CD7 (T cells); and megakaryocyte lineage cells co-express 
CD34 and CD61 (platelets, megakaryocytes)  (for review see –Kinniburgh & Russell 
1993).   
A more reliable discriminatory technique to isolate and identify hematopoietic 
stem cells uses combinations of cell surface markers, CD antigens.  For example, cells 
that are CD34+, CD38-, CD90low, CD117low, CD135+ or HLA-DR- are younger cells and 
are higher in the hierarchy of hematopoietic stem and progenitor cells (Broxmeyer 1995, 
Cardoso et al 1993b, Mayani & Lansdorp 1998, Rappold et al 1997, Traycoff et al 1994).  
The converse of this is also true - CD38+ cells that also co-express CD34 are  more 
committed progenitor cells (erythroid and granulocyte)(Mitsui et al 1993), and CD34 and 
HLA-DR are shown to be expressed on mature dendritic cells, B-cells, and erythroid 
progenitors (Kempuraj et al 1999).  In addition, cells that are CD34+ and Thy-1+ (CD90 – 
progenitor cell subset) express low levels of CD117 (c-Kit tyrosine kinase receptor).  The 
ligand for c-Kit is steel factor, also known as stem cell factor, which is believed to play a 
vital role in the proliferation and viability of hematopoietic cells.  CD34+ cells that are 
negative for c-Kit have been shown to give rise to long-term culture-initiating cells 
(LTC-IC), while in those high in c-Kit expression, LTC-IC were almost absent.  This 
pattern correlates with telomerase activity; in cells that are CD34+ CD38- or CD34+ 
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 CD117- have less mitotic activity, thus conserving telomeres, compared to CD38+ or 
CD117 high and low expressing cells (Sakabe et al 1998a, Sakabe et al 1998b).  The 
authors in this study, suggested cells that are CD34+ and CD38- or c-kit negative are 
more quiescent and therefore probably more primitive.  Although CD34 has been 
extensively used to identify hematopoietic stem and progenitor cells, studies have 
suggested there may be subset of stem and progenitor cells within cord blood that are 
CD34- and lineage negative (Goodell et al 1997, Osawa et al 1996).  However, the 
importance of this cell type in relation to cell transplantation requires further 
investigation.    
Within the hematopoietic stem cell population there is a subset of CD133+ 
(originally called AC133) cells that strongly co-express with CD34 bright cells.  There 
are two forms of the antigen that have been identified; CD133/1 is a cell surface 
glycoprotein and CD133/2 an intracellular protein (perinuclear label) (for review see  
Miraglia et al 1997, Yin et al 1997, for CD133/1 and Potgens et al 2001, for CD133/2).  
These antigens appear to be present on more primitive stem cells, in that, CD133/1 is not 
recognized in cultured human umbilical vein endothelial cells (HUVECs) or peripheral 
blood cells, but is expressed in human cord blood, fetal and adult bone marrow, and fetal 
liver cells (Yin et al 1997).  CD133/2 also shows no reaction with cultured HUVECs, but 
is expressed in placental tissue, specifically trophoblast cells(Potgens et al 2001).  This 
provides circumstantial evidence that CD133+ cells may be more a primitive stem cell 
than the CD34+ lineage- cells of HUCB.  However, further investigation into their 
proliferation and expansion capacity is needed before their clinical relevance is 
understood.   
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 CD markers have also been used to assist in identifying neural stem cells. CD133 
is consistently found in 90-95% of neurosphere cells whereas cells of the neurosphere 
express neither CD34 nor CD45.  Nor can CD34 and CD45 (common leukocytes 
antigen) positive cells form neurospheres (Uchida et al 2000).  Cells that are CD133+, 
CD34-, CD45- and CD24-/lo (B cell marker) that were isolated from human fetal brain and 
spinal cord (week 12) differentiated into neurons and glia, generated neurospheres, and 
had self-renewal properties (Tamaki et al 2002, Uchida et al 2000).  Additional markers 
are available to aid in identifying neural stem cells (for review see – Newman et al 
2003).  Using these tools, in vitro studies have clearly demonstrated the expression of 
neural phenotypes in a subset of mononuclear cells within HUCB.   
 
1.5 In Vitro Studies of HUCB Cells 
Sanchez-Ramos and colleagues (2001) initially cultured HUCB cells for 7 days in 
a proliferation media supplemented with N2 (neural proliferating component), epidermal 
growth factor (EGF) and basic fibroblast growth factor (bFGF).  Additional cells were 
cultured in differentiation medium consisting of the proliferation medium with the 
addition of all-trans-retinoic acid (Yamaguchi et al) and nerve growth factor (NGF).  
Immunocytochemical analysis revealed an increased expression of Musashi-1 (an early 
marker of neural precursors), β-tubulin III (a specialized tubulin found in neurons – 
TuJ1) and glial fibrillary acidic protein (GFAP - a marker for astrocytes) in HUCB cells 
that were cultured in retinoic acid (RA) and NGF.  RT-PCR analysis confirmed the 
presence of Musashi-1, the mRNA for neuronal markers, nestin and necdin, GFAP in RA 
and NGF treated cord blood cells (Sanchez-Ramos 2002, Sanchez-Ramos et al 2001). 
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 Since then, studies have confirmed and extended these results. β-mercaptoethanol 
has been shown to differentiate cultured HUCB cells towards a neural phenotype, which 
was confirmed by immunocytochemical expression of NeuN, neurofilament, and GFAP 
and by RT-PCR mRNA for nestin, neurofilament and MAP2 (Ha et al 2001).  A 
multipotent HUCB cell subset that does not express CD14, CD34, or CD45 was 
identified by Bicknese et al., (2002).  These cord blood cells when plated in a low 
glucose and more acidic media and supplemented with bFGF and hEGF differentiated 
and expressed both GFAP and TuJ1 after 7 day in culture.  Interestingly, both 
hematopoietic progenitors and osteoclast-like cells were eliminated in this media 
condition (Bicknese et al 2002).  Finally, some of the most elegant work elucidating the 
differentiation of HUCB cells into neural cells has been conducted by Buzanska et al., 
(2002).  Using a magnetic cell sorter, isolated CD34+ and CD45+ cells were used to 
provide a clonogenic cell subfraction of the mononuclear heterogeneous fraction of cord 
blood cells.  Following culturing in DMEM with selected growth factors the remaining 
cells showed a very high commitment (30-40%) to neuronal, astrocyte fates, and a 
modest proportion of oligodendrocytes (11%).  These clone-forming cells expressed 
nestin, but did not produce hematopoietic colonies.  Cells were immuno-positive for 
TuJ1 (a low level was present in untreated cells), MAP2, GFAP, and GalC 
(oligodendrocyte marker) after exposure to RA and brain-derived neurotrophic factor 
(BDNF).  While BDNF seemed to increase the number of astrocytes, RA treated cells 
alone had more neuronal expression.  In addition, when HUCB selected cells were co-
cultured with rat cortical cells for 4 days all three types of neural progeny were present 
(Buzanska et al 2002).   
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 These same investigators recently reported that after 2 years in culture, HUBC-
derived stem cells continue to display normal chromosomal patterns, proliferation, and 
self-renewal properties (Buzanska et al 2003a).  EGF and FGF receptor profiles appeared 
normal and both early and late passage cultures expressed internexin, Glutamate 
Receptor-2 (GluR2), Glutamic acid decarboxylase (GAD 65), GAD 67, and tyrosine 
hydroxylase (TH).  HPLC analysis confirmed that the HUCB stem cells produced and 
secreted serotonin (5-HT) and dopamine (DA) metabolites.  Differentiated HUCB stem 
cells also exhibit electrophysiological properties indicative of neurons including 
hyperpolarization-activated inward and outward currents (Buzanska et al 2003b).  
Missing from this area of research is the long-term potential and expansion capabilities 
of these cells.  More than likely the establishment of a “neural” stem cell line derived 
from HUCB cells that is both homogenous and reliable will be the next research step.  At 
this time, it remains unknown whether it is necessary to establish such a cell line in order 
to repair CNS diseases or disorders.  However, such a cell line would allow researchers 
to test the hypothesis of cell replacement to treat certain neurodegenerative and 
neurological disorders more easily.   
 
1.6 Transplantation Studies Utilizing HUCB Cells 
To date, there are comparatively few published papers demonstrating that HUCB 
cells express neural phenotypes after transplantation (Table 1.2).  Nonetheless, the 
accumulating in vivo data is quite consistent with the available in vitro data and points to 
the possibility that HUCB transplants may provide a means of ameliorating the deficits 
associated with a wide range of CNS diseases.  In addition, the in vivo evidence suggest 
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 that there are alternative mechanisms, besides cell replacement, in which transplanted 
HUCB cells are delivering therapeutic benefits in animal models of injury and disease.  
These mechanisms include but are not limited to the release of trophic and neurotrophic 
factors by HUCB cells and the attraction of endogenous factors or stem cells by cord 
blood cells to the site of injury/damage.  These alternative possibilities are discussed 
below with the appropriate study(s). 
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 Table 1.2 Significant Published CNS Transplantation Studies Using the 
Mononuclear Fractions of HUCB Cells 
Work Cited Animal Model & Cell Treatment 
Route & Time of 
Delivery/ 
Concentration of Cells 
for 
Transplant 
Behavioral Effects Immunocytochemistry Results 
 
Zigova et al., 2002 
Cell 
Transplantation, 
Vol. 11, pp 265-
274 
 
Developing rat brain 
Sprague-Dawley rats 
Cells treated with: 
1. DMEM, FBS + RA 
& NGF  
2. DMEM, FBS only  
 
*SVZ injection of cells 
in 1 day old neonates 
6 X 104 
 
No behavioral measures were taken. 
No detrimental or adverse effects noted. 
One month PT*:  
Both treatment cell groups: 
~2% positive for GFAP, with less than 0. 2% of positive 
for TuJ1 
 
 
Chen et al., 2001 
Stroke, Vol. 32,  
pp 2682-2688 
 
Transient MCAO  
Adult male Wistar rats 
HUCB cells used 
immediately after 
thawing  
 
Intravenous tail vein 
injection  
24 hrs or 7 days after 
MCAO 
3 X 106 
 
Motor neurological severity scores improved: 
24 hr & 7 day groups.  
Rotarod improvements: 
24 hr group only 
14 and 35 day PT  
More cells located in injured tissues in 24hr group. Both 
groups had some positive cells 
 for NeuN, MAP-2, GFAP, & FVIII* 
 
Willing, et al., 
2003a 
J of Neuroscience 
Research, Vol. 37, 
pp 296-307 
Permanent MCAO 
Adult male Sprague-
Dawley rats 
HUCB cells used 
immediately after 
thawing  
1. Intravenous femoral 
vein  
2. Intrastriatal injection 
In both groups cells 
delivered 24hrs after 
MCAO at 
concentrations of  
1 X106 or 2.5 X 105 
Both groups had functional improvements on a number 
of measures. 
1mo PT both groups improved on elevated body swing 
test. 
2mos PT femoral group showed improved motor 
asymmetry on step test.  
2mos PT more cellular debris in area of infarct of 
striatal group compared to femoral delivery where no 
cellular infiltration was noted.  Human nuclear staining 
did not clearly demonstrate survival of HUCB cells in 
injured area.  
 
Willing, et al., 
2003b 
Cell 
Transplantation 
Vol. 12, pp 449-
454 
 
Permanent MCAO 
Adult male Sprague-
Dawley rats 
HUCB and PBPC* 
cells were used 
immediately after 
thawing. 
   
Intravenous femoral 
vein 
Cells were injected 
24hrs after MCAO 
1 X106 
From 2 to 4 weeks PT HUCB treated rats increased in 
spontaneous activity and motor 
asymmetry was prevented in both groups measured on 
elevated body swing test. 
No immunocytochemistry or cell analysis performed. 
 
Vendrame et al., 
2004 
Stroke, Vol 35 (10) 
pp 
2390-2395 
 
 
Permanent MCAO 
Adult male Sprague-
Dawley rats.  HUCB 
cells were used 
immediately after 
thawing. 
 
HUCB cells 
intravenous infused. 
From 104 to 5 X 107 
cells injected.  
106 or more cells used significant behavioral 
improvement in step test and elevated body swing.  A 
reduce infarct size was also reported.  
Lu, et al., 2002 
Cell 
Transplantation 
Vol. 11, pp 275-
281 
TBI* 
Wistar rats 
HUCB cells were used 
immediately after 
thawing. 
Intravenous tail vein 
injection 
Cells were injected 
24hrs after TBI   
2 X 106 
At days 14 and 28 PT HUCB treated rats had 
improvements on rotarod test and on neurological 
severity scores.  
28 days PT Large number of human nuclei cells found 
in the brain and some double labeled for NeuN, MAP-2, 
and GFAP.  Most found in boundary zone of injured 
area. 
 
Table 1.2 (Continued) 
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 Table 1.2 (Continued) 
 
Work Cited Animal Model & Cell Treatment 
Route & Time of Delivery/ 
Concentration of Cells for 
Transplant 
Behavioral Effects 
Immunocytochemistry Results 
 
Saporta, et al., 2003 
J of Hematotherapy & 
Stem Cell Research 
Vol. 12, pp 271-278 
 
SCI* Hemicompression  
Adult male Sprague-Dawley 
rats 
HUCB cells were used 
immediately after thawing. 
 
 
Intravenous tail vein 
injection 
1. 1 day after injury 
2. 5 days after injury 
1 X 106 
 
Open field locomotor activity (Basso, 
Beattie, Bresnehan -BBB) after 
3weeks: 
5 day group had improved score 
compared to 1 day group.   
4 weeks PT HUCB cells were found 
only within the area of SCI.   
More cells were found in 5 day group 
than 1 day group. 
(Identification was difficult due to 
endogenous fluorescence.) 
 
Garbuzova-Davis et al., 
2003 J of Hematotherapy 
& Stem Cell Research 
Vol. 12, pp 255-270 
ALS  
Transgenic male mice 
B6SJL-TgN (SOD-G93A) 
1GUR ~9.5 weeks of age.  
HUCB cells were used 
immediately after thawing. 
 
Intravenous jugular vein 
injection 
Cells were delivered to pre-
symptomatic G93A mice at 
66.2 + 0.75 days of age.   
1 X 106 
Delayed progression of ALS for 2-3 
weeks and increased lifespan of 
treatment group. 
At 17 weeks of age PT HUCB treated 
mice finished footprint test faster 
compared to controls. 
10 to 12 weeks PT cells were found in 
the brain, spinal cord, and other 
organs.   
HUCB cell in CNS were identified 
with HuNu and double labeled for 
CD45, Nestin, TuJ1, and GFAP. 
 
* PT = post transplantation, PBPC = peripheral blood progenitor cells, 
FVIII = coagulation factor VIII, TBI = traumatic brain injury, and SCI = 
spinal cord injury, SVZ = Subventricular Zones. 
 
1.6.1 Normal Developing Brain 
Prior to initiating studies in animal models of CNS disease, mononuclear HUCB 
cells were transplanted into the subventricular zone of neonatal rat pups (1 day old) 
(Zigova et al 2002).  Given that the subventricular zone is an area known to promote stem 
cell survival and provide instructive signals for stem and progenitor cells, it offers a 
logical starting point to examine the engraftment and differentiation potential of HUCB 
cells into neural cells.  The mononuclear fraction of HUCB cells were cultured in either 
DMEM with fetal bovine serum or Neurobasal medium with RA and NGF.  Rat pups 
were transplanted with the cultured cells (60,000) and 30 days afterwards were sacrificed 
for immunohistochemical analysis of transplanted cells that survived and the 
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 corresponding phenotype.  Under both culture conditions, cells were found proximal to 
the transplantation site and in the overlying cortex and corpus callosum.  There was a 
greater distribution and survival rate of cells cultured with DMEM and FBS than with RA 
and NGF.  Double-labeling experiments confirmed the neural nature of at least some of 
the human transplanted cells that were labeled with either GFAP or TuJ1.  Qualitative 
analysis suggested that the majority of cells possessed an astrocytic-like phenotype and 
morphology.   
The study described above suggests that HUCB cells are capable of surviving and 
migrating within the developing, normal brain.  Future studies will certainly need to 
continue to explore the developmental biology and neural stem cell properties of these 
cells when grafted into the developing and aging brain.  However, the potential use of 
HUCB cells to treat the damaged brain is among the most exciting contemporary research 
areas.  Despite being a completely new field there are initial results demonstrating the 
functional effects of HUCB cells transplants in several different animal models of acute 
and chronic disease.  
1.6.2 Stroke 
Stroke is the third leading cause of death in the majority of developed countries 
and is a leading health care burden in all developed countries(American Heart 
Association, 2005).  Even though the incidence of stroke has declined over the past 
decades, progress in treating stroke has been disappointing.  Despite our continued 
understanding of the pathological underpinnings of cell death in stroke, there are no 
effective treatments for mitigating the loss of neurons in patients once that pathological 
cascade has been initiated.  Cell transplantation has been proposed as one means of 
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 repairing the stroke ravaged brain and recent studies suggest that systemic infusion of 
HUCB cells produces potent behavioral effects in animal models.  Indeed, recent data 
indicate that intravenously administered HUCB cells can survive, migrate to the site of 
injury, and provide functional recovery in a rat model of cerebral ischemia.  In a 
pioneering study, Wistar rats received a transient (2 hour) middle cerebral artery 
occlusion (MCAO) followed by a tail vein injection of HUCB cells (3 x 106 as a bolus 
injection) either 24 hours or 7 days after stroke (Chen et al 2001).  Animals were 
sacrificed at 14 and 35 days after MCAO and all animals showed significant lesions.  
However, no reduction in lesion volume was observed at either transplant time.  Detailed 
histological analysis revealed grafted HUCB cells within the ipsilateral cortex, subcortex, 
and striatum.  In addition, neuronal markers NeuN, astrocytic marker GFAP, and the 
endothelical cell marker, FVIII, were shown in animals transplanted at 24 hours after 
MCAO.  Associated with the survival of HUBC cells were improvements in behavioral 
indices.  A battery of tests including the rotarod motor test and the modified neurological 
severity score test (MNSS) was conducted at 1, 7, 14, 21, 28, and 35 days after MCAO.  
Rats that received HUCB cells 24hrs post stroke showed significant performance 
improvements on both tests, whereas treatment at 7 days produced less robust recovery 
with improved function seen only on the MNSS.  Therefore, this data suggest that a time 
dependent mechanism may be involved in delivery of the cells.  We examine this issue in 
more detail in Chapter 4. 
Subsequent studies have begun to examine whether the route of administering 
HUBC cells following MCAO, impacts behavioral recovery.  Sprague-Dawley rats 
received permanent MCAO and 24 hours later HUCB cells were injected either into the 
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 femoral vein (1 x 106 cells) or directly into the striatum (250,000 cells) (Willing et al 
2003a).  Behavioral tests conducted 1-2 months later included measures of locomotor 
activity, elevated body swing test, step test, and passive avoidance.  The pattern of 
behavioral recovery was dependent to some degree on the route of cell delivery.  Motor 
activity and passive avoidance testing improved in both treatment groups while 
performance on the step task (a measure of forelimb dexterity) improved in only those 
animals receiving HUBC cells via the femoral artery.  While it is tempting to speculate 
that the femoral route of administration was more effective than direct striatal injection, 
several outstanding issues remain including: the lack of definitive identification of HUCB 
cells in the brain (Figure 1.1), the differences in cell numbers transplanted in the two 
treatment groups, and the potential role of the immune/inflammatory response produced 
by the MCAO.  This last possibility is especially intriguing and the authors raise the 
possibility that the immune cells of the transplanted cord blood are attracted to the site of 
injury, which could help induce endogenous signals for the recruitment of stem cells 
within the animal or possibly the release of trophic factors from the HUCB cells 
themselves.  This could aid in the repair and the eventual behavioral improvements seen 
in these stroke animals.  In a second study, Willing, et al. (2003b), observed similar 
behavioral results in MCAO induced rats as in their first study.  This study also showed 
that human granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood 
progenitor cells delivered by femoral vein (1 x 106 cells) improved behavioral deficits 
seen in MCAO rats(Willing et al 2003b).  If a non-specific immunological effect does 
contribute to the behavioral recovery, it is of interest because in both studies cyclosporine 
was co-administered (to minimize graft rejection), and yet it did not alter the behavioral 
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 effects of HUCB cell transplants in rats following MCAO.  These results provide 
compelling support for the potential use of HUCB cells in treating stroke.  However, 
because the survival of HUCB cells at the site of damage appears to be relatively low 
(Figure 1.1) and the behavioral recovery, although present, is only partial, strategies are 
being developed for further improvement in the beneficial effects of HUCB transplants.   
Figure 1.1: HUCB Cells Transplanted into Stroke Rat Brain  
 
Figure 1.1 Fluorescence photomicrograph of striatum.  Converted into black and white (A) Cellular 
debris in lateral striatum associated with permanent MCAO (MCAO-only group).  DAPI was used 
to label cell nuclei within the striatum. With this method, a cellular infiltrate in the region of the 
infarct can be seen. These are small cells characteristic of either microglia or neutrophils in the 
same section as shown in A. (C,D) Higher magnification views from selected areas of the image in 
A. (E) Cellular debris in striatum in an animal from the femoral group. (F) Striatal group. (G) 
Normal contralateral striatum from the same animal as shown in E. Scale bar in B = 300 µm; for 
A,B; bar in D = 100 µm for C,D; bar in G = 50 µm for E–G. With permission from J Neurosci Res 
73(3), 296-307, (2003) Willing, et al. 
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 Not only have functional improvements in behavioral deficits of MCAO been 
seen, but reduction in the volume of the infarct have been reported(Vendrame et al 2004).  
In this study, MCAO rats were intravenously infused with 104 to 5 X 107 HUCB cells 24 
hours after surgery.  At 4 weeks after delivery of HUCB cells at the 106 or higher dose, 
the rats with MCAO showed significant improvements in behavioral measures.  More 
importantly, MCAO rats that were treated with 107 cells showed a reduced infarct 
volume, and cells were localized either to the infarct brain or in the spleen.  
Several important points are clear from theses stroke studies.  First, the behavioral 
improvements are consistent and contribute to a growing literature suggestive of the 
functional benefits of HUCB cell transplants.  Secondly, the study by Vendrame et al., 
provides the first clear evidence that transplanted HUCB cells can minimize the structural 
consequences of ischemic damage.  Third, the dose range of cells required for behavioral 
improvements and reduced infarct volume have been determined.  Fourth and last, “proof 
of principle” for both the behavioral improvement seen in the use of HUCB cells in the 
treatment of ischemic stroke and the intravenous delivery method has been established.   
 
1.6.3 Traumatic Brain Injury 
No class of CNS injuries is more steeped in history and frustration than traumatic 
brain injuries (TBIs).  Neurosurgery began with the treatment of head injuries as 
evidenced by what we know of medical practice in ancient civilizations.  Despite this 
long history, TBIs are much like stroke, in that, we have an enhanced understanding of 
the pathology associated with injury and have continually refined our principles of patient 
management.  In addition, TBI, similar to stroke, has no effective treatment.  While cell 
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 therapy offers theoretical promise for a wide range of CNS diseases, its promise is 
especially true for trauma if a non-invasive means of cell delivery could be developed.  
The exact nature of the localized trauma often times prohibits additional surgical 
intervention at the site until some time after the initial damage has occurred.  
Unfortunately, much of the potential benefit of an intervening cell therapy may be lost 
during this time.  In contrast, delivery of cells via the circulatory system would bypass 
these obstacles perhaps permitting sufficient cell delivery to the injured region resulting 
in anatomical and/or functional repair processes.  
To evaluate the potential of HUCB transplants in traumatic brain injury, Lu et al., 
(2002) examined the neurological benefits afforded by intravenous administration of 
HUCB cells in rats with contusive brain injury.  HUCB cells were injected into the tail 
vein 24 hours after injury and the rats were sacrificed 28 hours later for histological 
analysis of the migration of cells to the site of trauma.  The injected cells were distributed 
in the brain, heart, lung, kidney, liver, spleen, bone marrow, and muscle as demonstrated 
by immunohistochemical staining and laser confocal microscopy.  It would seem that 
there was preferential entry and migration of HUCB cells into the parenchyma of the 
injured brain.  The transplanted cells expressed the neural markers, NeuN and MAP-2, 
and the astrocytic marker, GFAP. Some HUCB cells integrated into the vascular walls 
within the boundary zone of the injured area.  Significant functional improvements were 
also produced as assessed by both the Rotarod test and the NSS (Lu et al 2002).   
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 1.6.4 Spinal Cord Injury 
Similar behavioral benefits of cord blood cells were observed in animals with 
spinal cord injury (SCI) (Saporta, et al., 2003).  SCI was induced by unilateral 
hemicompression with an aneurysm clip for 1 minute and HUCB cells (pre-labeled with 
FITC-conjugated cholera toxin) were intravenously injected either 1 or 5 days later.  
Behavioral recovery was determined using open field behavior at 1, 2, and 3 weeks after 
treatment.  Rats receiving HUCB cells at 5 days, but not 1 day after surgery, had gradual 
and significant improvements on the locomotor tests that were seen over the course of the 
study.  Histological analysis of these animals confirmed the presence of HUCB cells at 
and around the site of injury, but not in areas of necrosis or in the areas of intact spinal 
cord (Figure 1.2).  Consistent with the pattern of behavioral recovery, nearly twice the 
number of viable HUCB cells were present within the damaged spinal cord when 
transplanted at 5 days versus 1 day after surgery (Saporta et al 2003).  This is the first 
study to report that HUCB cells migrate specifically to the site of injury in the spinal cord 
and not to the contralateral side and the first to show that HUCB cells can improve motor 
behavior deficits in rat SCI model. 
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 Figure 1.2: HUCB Cells Transplanted into Spinal Cord Injury in Rats   
 
Figure 1.2  HUCB cells in the injured spinal cord 4 weeks after intravenous injection. Endogenous 
fluorescence was quenched with Pontamine Sky Blue (A) Fluorescent photomicrograph through the area of 
compression from a SCI only animal. No fluorescent HUCB-like cells were visible in these sections.  
Fluorescent photomicrograph of a section of spinal cord from a laminectomy-only animal that also received 
an intravenous injection of HUCB cells. No FITC-prelabeled HUCB cells are visible in these sections. (C) 
FITC-labeled HUCB cells (arrows) in a section from the spinal cord of a rat that received HUCB 5 days 
after compression injury within the area of compression. (D) Fluorescent photomicrograph through the area 
of compression of an animal that received HUCB 1 day after compression injury. FITC + HUCB cells 
similar to those seen in C were seen in these sections (arrows). Calibration bar: A, B, and D, 50 µm; C, 100 
µm. With permission from J Hematother Stem Cell Res, 12(3), 271-278, Saporta et al., (2003).  
 
 
1.6.5 Amyotrophic Lateral Sclerosis 
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Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is 
caused by a progressive degeneration of motor neurons.  In the United States, 1 to 2 
people per 100,000 develop ALS each year with men affected slightly more often than 
women(NINDS & NIH 2003).  Although ALS may occur at any age, it is most 
commonly diagnosed in middle-aged and older adults.  Over a period of months or years, 
ALS causes increasing muscle weakness, inability to control movement, and problems 
with speaking, swallowing, and breathing.  In general, weakness progresses steadily with 
no periods of improvement or stability leading to death, usually within 3 to 6 years.  
There is no cure for ALS at this time.  Current treatment for ALS focuses on helping the 
 person cope with symptoms and avoiding complications for as long as possible.  Cell 
therapy has been proposed as a possible replacement/repair strategy for the lost motor 
neurons.  However, the diffuse nature of the disease, a significant number of cells are 
required for transplantation, although in theory, cell replacement via stem cells injected 
into the circulatory system could be beneficial if the cells could migrate into the region 
proximal to the motor neurons.   
The mouse SOD-1 model of ALS provides a useful means of evaluating cell-
based neurorepair and neuroprotective strategies.  In a recent study 1 x 106 mononuclear 
cells from HUCB were administered intravenously (via the jugular) into G93A 
transgenice male mice at 9.5 weeks of age (prior to the onset of significant behavioral 
impairments)(Garbuzova-Davis et al 2003).  Significant benefits were observed in 
hindlimb extension and gait.  Grafted animals lost less weight over the course of the 
study and, most impressively, lived a significantly longer (2-3 weeks) than controls.  A 
detailed analysis of the survival and distribution of the injected HUCB cells revealed 
cells in the parenchyma of the brain, spinal cord, spleen kidneys, liver, lungs and heart.  
Some HUCB cells were immuno-positive for neural and astrocytic markers (TuJ1 and 
GFAP) within the parenchyma of the brain.  This study was the first to report that HUCB 
cells are capable of migrating to a progressive brain and spinal cord disease without 
occurrence of an acute traumatic injury.  Future studies should examine this approach in 
other progressive degenerating diseases such as PD, HD, and AD.  Although there have 
been studies demonstrating longer life span expectancy in animal models of degenerative 
disorders treated with cord blood cells (Ende, Weinstein, Chen,  & 2000; Ende, Chen, & 
Ende-Harris, 2001; Ende & Chen,  2002), they did not examine the size of lesion, grafted 
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 cell survival, location of the cells, immuno-markers, or optimal time periods in which to 
administer the cells.  
 
1.7 HUCB Stem Cells for Gene Therapy 
Gene therapy, or the manipulation of human genetic material to produce a 
therapeutic effect, is a maturing scientific field and hematopoietic stem cells are 
promising targets for gene therapy.  Like other areas of gene therapy, the use of modified 
hematopoietic cells suffers from low and variable transfection efficiency, uncontrolled 
production of foreign gene products, and poor safety profiles.  Nonetheless, significant 
progress has been made in transfecting hematopoietic stem cells using both viral (sendai 
virus, simian foamy virus, human foamy virus, lentivirus, and adenovirus) and non-viral 
(centrifugal enhancement and particle-mediated gene delivery) methods (Buchet et al 
2002, Falk et al 2002, Hughes et al 2002, Mitta et al 2002, Rosenqvist et al 2002, Watson 
et al 2003).  In addition, cryopreserved HUCB cells may offer a certain advantage in the 
field of gene therapy research (as discussed early) in that they express a high level of 
amphotropic retrovirus receptors and amphotropic retrovirus receptors are widely used 
for transduction of gene vectors (Orlic et al 1996).  Figure 1.3 represents one of the viral 
methods using green fluorescent protein (GFP).   
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 Figure 1.3: HUCB Cell that are Labeled with Green Fluorescent Protein 
Figure 1.3 Green fluorescent protein labeling of HUCB. 
Using the lentiviral vector approach (provided by Dr. Didier 
Trono), HUCB cells (A, phase contrast) exhibit the green 
fluorescent protein (GFP) in vitro (B, FITC fluorochrome). In 
addition, following transplantation into the striatum, HUCB 
cells retain GFP epifluorescence at least up to 6 months of 
graft maturation (C, magnified in D). Figure kindly provided 
by Dr. Didlier Trono and with permission from Newman et 
al., (2004) Expert Opin Biol Ther, 4(2), 121-130. 
 
 
 
The results obtained, using Sendai viral mediated transfection, are particularly 
promising.  Very high transfection of GFP has been achieved by using CD34+ HUCB or 
BM cells (>80%) and other HUCB progenitor cells (Woods et al 2001, Woods et al 
2003).  Efficient gene transfer was independent of cell cycle and in vitro cell 
differentiation studies confirmed that gene transfer occurred in progenitor cells of 
multiple lineages (Luther-Wyrsch et al 2001) indicating that this system provides very 
high gene transfer rates while maintaining the cells’ ability to reconstitute the normal 
compliment of hematopoietic lines. 
In theory, stem/progenitor cells within the mononuclear fraction of HUCB offer 
yet another unexplored means of enabling gene therapy for the CNS.  Cell-based gene 
therapy is hampered by the lack of an abundant, safe, and immunologically acceptable 
source of tissue.  Conceivably, HUCB stem cells could overcome this limitation because 
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 of their ability to evade detection by the host immune system and continue to secrete a 
therapeutic compound.  As described above, several of in vivo studies have confirmed 
that HUCB cells survive following engraftment into the brains of xenogeneic hosts (i.e. 
human to rat).  The continued survival of HUCB cells in these studies cannot be solely 
attributed to the adjunctive pharmacological regimen, such as cyclosporine, but rather it 
reflects some inherent aspect of the transplanted cells.  A recent study by Weiss and 
colleagues (2003), clearly shows that a subset of umbilical cord matrix cells from pigs 
differentiate into glia or neurons and survive following transplantation in rat brain for 
more than six weeks without triggering any recognition by the immune system (Weiss et 
al 2003).  The authors suggest that the in vivo differentiation of cord blood cells into 
neurons might provide a unique approach to treating CNS diseases.  This may be the 
case; however, this also provides a new opportunity to engineer and transplant stem cells 
from HUCB that could produce a desired therapeutic protein such as dopamine or GDNF 
for the treatment of PD.  If longer-term studies confirm the stable transfection and 
longer-term survival of HUCB cells following transplantation this may create a new arm 
of xenotransplantation research that could potentially obviate many of the issues 
associated with tissue rejection. 
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 1.8 Clinical Studies using HUCB Cells 
1.8.1 Transplantation of HUCB cells into Patients with Inborn Errors in 
Metabolism 
As mentioned HUCB cells, along with bone marrow cells have been used to treat 
various nonmalignant and malignant hematopoietic diseases, such as juvenile chronic 
myelogenous leukemia, Fanconi's anemia, and in patients with neuroblastoma that have 
varying clinical outcomes depending on the stage of the disease at time of transplantation 
and the disease itself.  In addition, HUCB cells have been used to treat 
lysosomal/enzymatic disorders, such as Krabbe disorder and Maroteaux-Lamy 
syndrome.  Krabbe disease is caused by a deficiency in galactocerebrosidase (GALC), 
which results in insufficient myelin formation in the peripheral and CNS.  The majority 
of infants diagnosed with this disorder die before reaching 2 years of age, while the 
prognoses in adults is quite variable.  Hematopoietic stem cells have been used to treat 
patients with Krabbe disease (Wenger et al 2000), and although this treatment decreases 
the symptoms, it does not eliminate or cure it.  Infants with this disorder have been 
shown to have a longer lifespan if they receive hematopoietic stem cells within the first 
two weeks of life.   
Snyder and colleagues recently presented their findings, at the America Society 
of Neural Transplantation and Repair annual conference (2003), on a 21-month-old 
female infant suffering from Krabbe leukodystrophy, who received HUCB cells of male 
origin, and survived for a year after transplantation (Kosaras et al 2003).  This study 
showed that upon postmortem examination of the brain, by FISH and 
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 immunocytochemistry analyzes, the transplanted HUCB cells were located in both white 
and gray matter, the ventricular ependyma, and within blood vessels throughout the host 
brain.  Furthermore, HUCB cells were determined to differentiate into microglia, but not 
neural cells and the authors proposed that these cells could be producing GALC.  This 
finding directly supports the pre-clinical studies discussed here that suggest that 
transplanted HUCB cells are acting through other mechanisms besides the differentiation 
of these cells into neural phenotypes to produce the improved behavioral results observed 
in animal models of injury.   
The FDA has already approved clinical trials using HUCB cells for hematologic 
malignancies, aplastic anemia, immunodeficiency diseases, and metabolic disorders 
(Thomson et al 2000, Wagner et al 1995).  While these clinical trials are not for 
neurological disorders, the level of comfort that regulatory agencies already have with 
this general approach together with the data collected from ongoing trials (related to 
dosage, GVHD, cell survival, safety of the HUCB cells, and their efficacy) will facilitate 
entry into clinical trials for cellular transplantation therapies.  With over 1500 cord blood 
transplants performed worldwide, a strong safety and efficacy database is being compiled 
(Gluckman et al 2001, Laughlin et al 2001).  Although no official clinical trials for 
neurological disorders are in progress, various media sources have reported that HUCB 
cell transplants for ALS, stroke, and Sanfilippo Syndrome have been performed.  
However, without corroborating scientific data to review: these reports are insufficient to 
determine the effects of the HUCB cells on the treated patients. 
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 1.9 Conclusions Thus Far 
 
Cell transplantation for CNS diseases has always held tremendous medical 
potential.  Nevertheless, despite the generally promising clinical results of numerous 
strategies, widespread clinical evaluation has been difficult.  The most obvious example 
of this is the use of fetal neural tissue.  Even though fetal grafts, survived and produced 
functional benefits in pre-clinical models, and have been suggested to be beneficial in 
small clinical trials, the limited tissue availability and ethical concerns have seriously 
hampered development of this approach.  Described here is an alternative approach to the 
traditional problems of cell therapy that focuses on the use of HUCB as a rich and 
transplantable source of non-embryonic or adult stem cells that appear to be capable of 
exerting pronounced effects even when administered systemically. 
 
1.10 Explanation of Study and Overall Purpose 
 
The studies within this manuscript were preformed to answer questions that will 
advance the potential of HUCB cells in the field of cell therapy and repair.  In the 
research that was presented, in this chapter, three areas clearly required further 
exploration; the ability of HUCB cells to migrate to the injured tissue, the 
chemoattractants (if any) within the damaged tissue and the factors responsible for the 
improvement in behavior.  We examined basic characteristics that were needed to 
proceed with the planned studies, such as, the average diameter of the cells, their 
phenotypes in culture, the ability of these cells to proliferate in culture, their ability to 
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 migrate to known chemoattractants along with the optimal time, testing of several assays 
in which to measure migrating cells, protein assay to standardized protein amount in 
migration studies, and migration to the young rat brain, which we believed at the time 
could be use as a positive control.  These findings are presented in Chapter 3.  
The ability of HUCB cells to migrate to injured tissue, which is especially 
important when using systemic administration, and the optimal time after injury to 
deliver these cells was examined.  Initially experiments were designed to address the 
cells’ ability to migrate in a variety of animals models of disease or injury of the CNS.  
After the initial migration experiments with several animal models of injury (Chapter 3) 
one in particular (ischemic rat) showed significant clinical and basic science relevance, 
and this study is present in Chapter 4.  The ischemic rat migration study was expanded to 
determine some of the cytokines or chemokines present in the ischemic tissue (Chapter 
4), and the ability of HUCB cells to produce cytokines/chemokines, these data are 
presented in Chapter 5.  Compared to the number of cells that were injected, in the 
HUCB cells transplantation studies, few cells were found at the site of injury.  This is 
very interesting due to the significant improvements in behavior that were presented in 
the animal models of injury therefore; we felt exploration in this area was essential.  
These experiments and results are present in Chapter5.  In addition, the relevance to 
clinical and basic sciences from these studies is discussed in Chapter 6.  
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Chapter 2 
 
2.0 Chemotactic Assay and Cell Migration 
 
2.1 Introduction 
 
Cell migration is an essential component of embryonic development, adult 
maintenance (such as inflammatory response and wound healing), and tumor metastasis.  
Additionally, cell migration is of critical importance in the field of cell transplantation.  
Stem cell replacement therapy is one of the more promising treatments for certain 
neurodegenerative disease and traumatic insults such as Parkinson’s disease and 
ischemia.  Scientific studies are rapidly being published regarding the capability of 
transplanted stem cells to regenerate, integrate, and/or supply trophic factors to the target 
tissue.  However, a major dilemma within this field is the migratory behavior of cells 
once transplanted, whether locally in the target tissue (e.g. intrastriatial) or distally (e.g. 
intravenous injection).  In addition, if cells migrate to areas beside the target tissue this 
could cause problems, therefore it is essential that these cells are tracked and safety 
studies performed.    
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There are real limitations in cell migration research.  In vivo, it is a slow and 
labor-intensive process to track cell migration and the migrated cells are only identified 
after histological examination.  There is the possibility of using magnetic resonance 
 imaging (MRI) system to track labeled cells.  However, MRI systems are rather costly 
and not many researchers have access to these systems.  In addition, without disturbing or 
invading the brain, .there is no in vivo method to study the possible factors that induce the 
migration of cells to the injured tissue in the brain.  Endogenous microenvironment 
factors at the site of injury or damage may serve as chemoattractants for the migration of 
the transplanted cells or may inhibit the migration.  Again, only by invading the brain or 
after tissue processing are those factors possibly identified.  Furthermore, both the 
disruption of the brain and the tissue processing may interfere with obtaining reliable 
results. 
The homing or migration of stem cells to a chemoattractant(s) has been 
determined in bone marrow transplantation.  Hematopoietic stem cells once transplanted 
will home to the bone marrow, leave the peripheral circulation, become stable and 
proliferate in extravascular space of the bone marrow cavity, thus serving to reconstitute 
the hematopoietic system (Whetton & Graham, 1999).  Yet, even in this area of research, 
the migration and trafficking of cells and the molecular mechanisms regulating these 
interactions are poorly understood.   
There are a number of studies that have reported the migration of stem cell and 
neural stem cells to the sites of degenerative or injured tissue (reviews see - (Keirstead, 
2001; Zigova, Snyder, & Sanberg, 2002).  Moreover, when compared to our knowledge 
of cellular migration during development, inflammatory response and wound healing, 
which is limited, our understanding of cell migration from allografts or xenografts to 
injured tissues is in infancy.  A further understanding of the intrinsic and extrinsic  
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 mechanisms and signals involved in the migration of cells to injured or damaged tissue is 
certainly warranted.  However, the first step is to determine systematically whether a 
given population of cells will migrate to the damaged tissue.  The second step would be 
to determine whether there is an optimal time at which to administer the cells.  In 
addition, the third step would be possible chemoattractant factors in the damaged tissue, 
and to identify the cytokines or chemokines that may be released by the transplanted 
cells.  
 
2.2 Background on Chemotactic Assay and Cell Migration 
 
The chemotactic assay Boyden Chamber – (Boyden, 1962) was originally 
developed for and is now a standard method in the area of cancer and inflammatory 
response research.  This type of transmigration assay has been widely used to study 
leukocyte, fibroblast, and endothelial cell migration to chemoattractants, chemotactic and 
adhesion stimulants, and/or chemokines.  Although the methodologies and types of 
chambers have advanced, the basic function remains the same.  In addition, these types of 
chambers or apparatus allow control over the chemoattractants, stimulants, and type of 
migration.  There are three basic types of cell movement/migration.  Chemotaxis, in 
general, refers to the movement of leukocytes or cells induced by a chemotactic stimulus 
and typically, the cells are attracted in a positive gradient (those moving towards the 
agent) or negative gradient (those moving away from the agent).  Chemokinesis is the  
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 migration of cells in a random direction by a chemoattractant (stimulant to move), and 
random migration refers to undirected and spontaneous migration of cells.   
The process of cell migration is closely coupled to the presence of chemokines 
(chemoattractants), which belong to the super family of cytokines; these are also referred 
to as chemotactic cytokines.  Chemokines in the range of 8 to 17 kD molecular mass have 
been shown to be a chemoattractant selective for leukocytes, the reason for this is still 
unclear (Benveniste, 1998).  Recently several studies have examined factors influencing 
the migration of hematopoietic progenitor cells (HPC) in the bone marrow environment.  
HPCs are known to migrate to bone marrow during transplantation and fetal 
development.  These cells also migrate from bone marrow to the peripheral blood in 
response to cytokines (Imai et al., 1998; Kim, Pelus, White, & Broxmeyer, 1998).  The 
mobilization of stem cells within the stromal layer of bone marrow and peripheral blood 
is a complex interaction of numerous cytokines (for review see – Horuk, 2001; Pelus, 
Horowitz, Cooper, & King, 2002).  Stromal cell-derived factor-1 (SDF-1) has been 
shown to be a strong chemoattractant for HPCs and has induced migration of CD34+ cells 
from HUCB (Kim & Broxmeyer, 1998) using chemotactic assays, and is believed to play 
a vital role in the homing of HPC to bone marrow (Voermans, Anthony, Mul, van der 
Schoot, & Hordijk, 2001).  SDF-1 is classified as a CXC-chemokine and is a 
chemoattractant for monocytes and lymphocytes.  The receptor for SDF-1 is CXCR4 
(also called Fusin and LESTR), which is a G-protein coupled receptor, typical for 
chemokines.  Another chemoattractant, somatostatin (SST), which is not a chemotactic 
cytokine, but a regulatory peptide produce by neuroendocrine and immune cells, has been 
reported to attract immature hematopoietic cells (CD34+ CD117+) in a transwell 
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 migration assay (Oomen, Hofland, van Hagen, Lamberts, & Touw, 2000).  Interestingly, 
the attractant and homing molecule for leukocytes, L-selectin, was reported not to attract 
hematopoietic stem cells (CD34+) (de Boer et al., 2002).  The use of the in vitro 
migration assay is a well-established method for screening a select cell population to 
chemoattractants, and the proven chemoattractant, SDF-1, for hematopoietic stem and 
progenitor cells was used in this study as a positive control.  
 
2.3 Migration Induced by Inflammation 
 
The migration of white blood cells in inflammatory and wound response is well 
documented.  In brief, the inflammation response occurs by a number of separate and 
simultaneous events.  There is an acute vascular response, in which the blood vessels 
widen to increase blood flow to the inflamed area, leading to an increase in vascular 
permeability allowing diffusible substances to enter, and an acute cellular infiltration 
occurs through chemotaxis or movement of the proinflammatory cells.  The hallmark of 
inflammation is the appearance of neutrophils in the tissue and they migrate directly 
through the blood vessel walls to the site of injury.  There is also a change in biosynthesis 
profiles of many organs and the release of several substances including cytokines.  
Lastly, there is the activation and migration of immune cells to the inflamed site.  The 
migration of cells to an injured area is regulated by a variety of signaling molecules that 
are produced locally by mast cells, nerve endings, and platelets in which there is a 
selective production of adhesion, chemokines, and inflammatory molecules (cytokines) 
(Johnston & Butcher, 2002).  Initially, leukocytes are adherent to endothelial cells by L-
52 
 selectin (CD62L), which is expressed by leukocytes.  When cytokines are activated, 
endothelial cells produce E-selectin (CD62E), and the receptors for this adhesion 
molecule are expressed on neutrophils, monocytes, eosinophils, and subsets of 
lymphocytes.  Only after cytokine activation, is P-selectin (CD62P) released from 
granules of platelets or Weibel-Palade bodies of endothelial cells and the target cells are 
the same as E-selectin (Lorant et al., 1995; Shah et al., 2002; Smith, Kunjummen, 
Kishimoto, & Anderson, 1992; Stanimirovic, Wong, Shapiro, & Durkin, 1997).   The 
integrins, which are expressed by leukocytes, monocytes, macrophages, granulocytes and 
a variety of other cell types, allow stronger adherence of neutrophils to the endothelium, 
where they crawl and migrate to the tissue in response to a chemoattractant gradient 
(Johnston & Butcher, 2002).  Other molecules also act as chemoattractants for specific 
types of white blood cells, escaping into the blood and inducing the production of 
leukocytes within the bone marrow (Alberts et al., 1994) 
Little is known about the mechanisms involved in stem cell migration.  We know 
now that stem and progenitor cells migrate from “organ to organ” during embryogenesis 
through adulthood (Broxmeyer, 1998), and we are just beginning to understand the 
factors and circumstances that drive or direct these cells to their targets.  The process of 
cell migration itself is complex and varies in accordance with the conditions of migration.  
For example, during embryonic development cellular migration is conceptualized within 
the context of tissues and organ formation.  The migrating cell and its resulting 
phenotype are exclusively dependent upon the three germ layers formed at gastrulation.  
Embryonic stem cells proliferate and their progeny undergo a process of progressive 
lineage restriction finally generating differentiated cells that form mature tissue.  For 
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 example, cells from the endoderm layer will migrate and give rise to the digestive tract 
and its associated components and glands (e.g. the esophagus, stomach, salivary glands, 
liver, lungs etc…), while the mesoderm layer cells give rise to the supporting muscular 
and fibrous elements.  The ectoderm layer cells, which form the epidermis, will give rise 
to the entire nervous system through neurulation.   
The involvement of the extracellular matrix (EMC) is vital for cellular migration, 
along with the complex signaling of several cytokines, integrins, selectins, and other 
adhesion molecules and receptors that create a cascade of intracellular and extracellular 
events that participate in the directing of embryonic cell migration.  For instance, cell 
adhesion to the ECM is essential; however, there is a necessary loss of cell-cell contact 
when cells move through the ECM during mesoderm and neural crest formation (Perris & 
Perissinotto, 2000).  In addition, cells acquire migratory properties when they split off 
(delaminate) from the ectodermal layer and transit from the epithelial to the mesenchymal 
layer (Locascio & Nieto, 2001; Perris & Perissinotto, 2000).  
 In the development of the CNS, stem cells reside, proliferate, and migrate from 
two germinal matrices.  The neuroepithelium (also called ventricular zone and ependymal 
layer) is the primary source of neurons and is derived from the neuroectoderm of the 
neural plate.  The second germinal matrices consist of the subventricular zone, which is 
close to the ventricle and the external germinal/granular layer, which is farther away 
(Committee., 1969). Stem cells in this region give rise to mostly granular cells.  The 
neuroblast cells (precursors of neurons) migrate away from the matrices, stop 
proliferating, and differentiate (Altman & Bayer, 1995).  The stem cell proliferation, 
differentiation, and migration are regulated by a strict timetable.  Neurogenesis is known 
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 to continue in the postnatal period, mainly in the subventricular zone, the external 
granular layer of the cerebellar cortex and perhaps in the dentate gyrus of the 
hippocampus (Altman & Bayer, 1995; Peretto, Merighi, Fasolo, & Bonfanti, 1999). 
Until recently, only embryonic stem cells were thought to be pluripotent since 
they must form all tissue types.  However, a certain degree of plasticity is now 
recognized with adult stem cells, in that, some adult stem cells are capable of acting and 
expanding outside where they reside and assist in regeneration of distal tissue (Blau, 
Brazelton, & Weimann, 2001).  Moreover, adult neural stem cells that reside within the 
subventricular zone (subependymal layer) of the forebrain, migrate a great distance 
within the rostral migratory stream to reach the olfactory bulb and regenerate this 
population of cells (reviews see - Gritti, Vescovi, & Galli, 2002; Peretto et al., 1999).  
The external granular proliferative layer in the dentate gyrus of the hippocampus is also 
known to give rise to astrocytes and neurons (Kuhn, 1996; Okano, Pfaff, & Gibbs, 1993).  
With global ischemia (Liu, Solway, Messing, & Sharp, 1998) and induced seizure, this 
area showed an increase in neurogenesis.  Additionally, in neuronal injury models, 
transplanted adult neural stem cells have been shown to migrate to the site of damage 
(Akiyama et al., 2001; Herrera, Garcia-Verdugo, & Alvarez-Buylla, 1999; Kurimoto et 
al., 2001).    
2.4 Summary  
Very little is known about the properties involved in the migration of HUCB cells. 
We do know HUCB cells will migrate towards ischemic brain tissue extract (Chen et al., 
2001).  When administered intravenously to rats that have undergone traumatic brain 
injured or ischemia, HUCB cells will survive and migrate to the damaged brain area 
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 (Chen et al., 2001; Lu et al., 2002).   Together the results suggest that some signal may be 
attracting and/or inducing these cells to migrate towards these tissue extracts.  From what 
has been presented so far it is plausible that HUCB cells, especially the stem and 
progenitor cells, would migrate to the developing, degenerating, and/or injured brain.  
Chapter 4 and 5 will present our findings on the probable cytokines and chemokines that 
might induce the migration of HUCB cells to injured or damaged tissues and those the 
could be produced by these cells once at the site of injury, which could aid in the 
behavioral recovery that has been seen in the animal models of injury.    
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Chapter 3 
 
3.0 Progression of the Dissertation Studies, Disease Models, 
and Preliminary Data 
 
3.1 Progression of the Dissertation Studies  
 The use of HUCB cells as a possible treatment for certain CNS diseases or 
injuries is becoming increasingly feasible.  However, as discussed in Chapter 1 and 2 
there are many issues to address for progress to continue in this area of research.  The 
study presented in this and the next two chapters addresses some of those issues: 1) 
Whether HUCB cells have the ability to migrate to injured brain. 2) The optimal time or 
“window of opportunity” at which to administer the cells based on the migration data. 3) 
The identification of chemokines and chemoattractants in tissue extract from stroke brain 
(that may have induced HUCB cells to migrate).  4) And the numerous cytokines 
produced by HUCB cells in response to their microenvironment are identified.  Figure 
3.1 is a flow chart of the Dissertation Studies. 
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 Figure 3.1 Dissertation Studies  
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 Initially, the study was designed to investigate the migration of HUCB cells to 
several models of injury or disease (Parkinson’s Disease, Stroke, Sanfilippo Syndrome 
and aging brain).  The cell migration experiments using tissue extracts from these animal 
models were accomplished for all models except aging brain.  The aging brain was not 
studied, because of the long wait period and the expense in obtaining aged rats.  
However, instead the migration of HUCB cells to the young rat brain was performed, 
results of which are presented in preliminary data section of this chapter.  
In addition, during the initial migration experiments, one of the animal models in 
particular became of great interest - middle cerebral artery occlusion (MCAO) rat model 
of stroke.  The preliminary migration assay data from this model showed a time 
dependent factor indicating there could be a “window of opportunity” for delivery of 
these cells after ischemic stroke that could result in the most cells migrating to the site of 
injury.  Therefore, in order to tease apart this phenomenon, the migration of cord blood 
cells to rat ischemic tissue extracts, at several time points after the induction of stroke (4 
hours to 1 week), and for three areas of the brain (striatum, hippocampus, and the frontal 
cortex surrounding the striatum) was performed (see - Chapter 4).  The next logical step 
was to identify the mechanism(s) that may be responsible for inducing migration of these 
cells.  Therefore, the chemokine(s) or chemoattractant(s) present in the striatal ischemic 
rat tissue extracts were determined.  This data is presented in Chapter 4.  Also of 
importance was to determine whether the cord blood cells were producing 
cytokines/chemokines that may be aiding in the functional recovery that has previously 
been reported when HUCB cells are transplanted into MCAO rats (reviewed in Chapter 
1) (Chen et al., 2001; Vendrame et al., 2004; Willing, Lixian et al., 2003; Willing, 
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 Vendrame et al., 2003).  The cells were cultured in various conditions to determine how 
microenvironments might influence their cytokine/chemokine production and these 
cytokine profiles are presented in Chapter 5.  Further characterization, by performing 
ELISAs on the most significant chemokines in condition media of cultured HUCB cells 
(Chapter 5) and those from the striatal extracts were performed (Chapter 4).  Lastly, to 
characterize these cells further, migration assays of cord blood cells to monocyte 
chemoattractant protein-1, (MCP-1), (which was present in both the tissue extracts and 
condition media) and the stimuli IL-3 and thrombopoietin (TPO) (which were added to 
the cells in culture), were completed.  In concentrating on one model of injury (stroke), 
the study developed further than the several migration assays alone, and the results 
provide data that have true clinical relevance for the utilization of HUCB cells in the 
treatment of human injuries and/or diseases.   
 
3.2 Background and Preliminary Data 
Several issues needed to be address before beginning the migration and cytokine 
assays, such as the mean diameter of cord blood cells, basic culturing and proliferation 
ability, general morphology and phenotypes of the cells, develop and optimize the 
migration assay, and perform protein assays to standardize tissue extracts.  These are 
presented in the following sections of this chapter.  The preliminary experiments that 
were required in order for the main studies to occur and the experimental results from the 
other animal models used are discussed.  The methods for each are presented along with 
the findings. 
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 3.2.1  Migration Apparatus 
Until recently, the most common way of performing migration assays was to use 
Transwell plate (Corning) or the traditional Boyden Chamber.  However, these apparatus 
proved to very expense due to the small number of samples the plates hold.  Furthermore, 
the Transwell did not allow for true gradient migration, because the top well sit within the 
media or the chemoattractant.  The decision was made, after extensive testing, to use the 
96-Chemotx® Chamber plate (Neuro Probe, Inc.).  This plate allows 96 samples to be run 
simultaneously, and the cells must be attracted or stimulated to migrate due to the design 
of the plate (Figure 3.2).   
Figure 3.2 Depiction of Migration Chamber 
A.       B. 
   
        
Figure 3.2 Illustration of 96-Chemotx® Chamber from Neuro Probe, Inc. 
(A.) This diagram shows a single top well with a porous membrane and a 
hydrophobic coating surrounding it.  (B.) A diagram of top well (side 
profile) representing how cell suspension is kept in place.  Cell 
concentrations are placed on the top well and tissues extracts are placed in 
the bottom well. (C.) Shows the 96-well chamber fully assembled.  
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 3.2.2 Cell Diameter of HUCB Cells 
 One study previously explored the migration of HUCB cells to ischemic brain 
tissue extract (Chen et al., 2001).  However, in their study a membrane with 8µm pore 
size was used.  The preliminary data present here shows that the average size of HUCB 
cells at 1 day in vitro (DIV) and 3 DIV to be between 6 and 8µm, depending on the 
sample (Figure 3.3).  This finding suggests that the pore size used by Chen et al. (2001) 
allowed cells to drop through the membrane instead of truly migrating to the extract.  
Therefore, the all migration experiments in this study used a pore size of 5µm on the top 
membrane.  There were no significant differences between the diameters of the cells at 1 
DIV compared to those at 3 DIV or between the samples.  Typically, in our hands, 
HUCB cells began to differentiate at day 4 in culture in which distinct morphologies are 
apparent by 7 DIV.   
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Figure 3.3 Average Cell Diameters of HUCB Cells  
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Figure 3.3 The graph represents the average cell diameter of HUCB cells.Different lots 
of HUCB cells, 5 lots total, were cultured in DMEM, with 5% FBS and Gentamicin (50 
µg/mL) for either 1 or 3 DIV.  Initial seeding density was 106/cm2 and 500 cells were 
randomly measured per sample and day.  The cells measured on day 1 were not from the 
same plate as those on day 3.  Live cells were measured for their diameter with an image 
analysis program, ImagePro-Plus (Version 5.0, Media Cybernetics, San Diego, CA).  
Data is presented as mean + SEM.  There were no significant differences in the diameter 
of the HUCB cells between lots or days in culture. (Student’s T-test, p<0.05) 
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  3.2.3 HUCB Cells in Culture 
 To establish the general characteristic of the cord blood cells and to ensure that 
they would sustain and grow, in our hands, the cells were cultured for different periods 
and proliferation and live/dead assays were performed.   
3.2.3.1  Preparation of HUCB Cells 
Cryopreserved mononuclear fractions of HUCB cells were obtained from Saneron 
CCEL Therapeutics, Inc.  Cells were thawed and pipetted into 9 mL of media [clear 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad) with 10% FBS and 
1 µL/1mL of Gentamicin (Sigma, St. Louis)].  Cells were centrifuged at 400 g for 15 
minutes, the supernatant was removed, cells were resuspended in 1 mL of media, and 
viability assessed using the trypan blue dye exclusion method as described previously 
(Zigova & Newman, 2002).  Cord blood cells were then plated in either 8-well chamber 
slides, 35 mm dishes (Nunc, Naperville), or low adherence 6-well culture dishes 
(Corning, Corning) at a seeding density of 105/cm2 and placed in water jacket incubator 
set at 370C and with 5% CO2 ..     .  
3.2.3.2  Phenotype of HUCB Cells 
68 
To determine phenotype and morphology HUCB cells were cultured from 1 to 14 
days in 8-well chamber slides, as described above.  The media was changed very 3 days 
until cells were fixed.  Phenotyping of the cell used immunocytochemistry methods.  
Media was removed and cell cultures were fixed in 4% paraformaldehyde (pH 7.4) and 
then thoroughly washed (3 x 10 min each) in 0.1 M phosphate-buffered saline (PBS).  
Then the cultured cells (slides) were incubated for 1 hr at room temperature in 10% 
normal goat serum and 0.03% Triton X-100 in 0.1 M PBS for blocking.  Slides were then 
 incubated for 24 hrs at 4°C with the primary antibody directed against one of several 
hematopoietic cell markers with PBS containing 0.03% Triton X-100 and 2% normal 
goat serum.  The control slides were handled in the same manner except that the primary 
antibody was omitted.  Primary antibodies used were CD45 leukocyte common antigen 
(BD PharMingen; 1:500), CD133/1 (AC133) cell surface antigen present on 
hematopoietic stem and progenitor cells (MACS; 1:50), and CD34 (TUK3) 
transmembrane glycoprotein expressed on hematopoietic progenitor cells (Santa Cruz; 
1:50).  Rhodamine or fluorescein conjugated secondary antibody were used against 
primary at 1:500– 800 (Molecular Probes, Inc.).  Slides were then rinsed in 0.1 M PBS, 3 
x 10 minutes, coverslipped with either 95% glycerol or Vectashield mounting medium 
with DAPI (Vector Laboratories) to help visualize cells and quantify immunostaining, 
and then examined by standard epi-illumination fluorescence microscopy.  Results are 
presented in Table 3.1 and were quantified by counting cells in 80 random fields for 8 
slides per antibody by investigators blind to the conditions. Scores were then tabulated as 
percentage of total cells.   
In Table 3.1 the stem and progenitor cells showed a decrease in number that 
corresponded to the length of time the cells were kept in culture.  These results are in 
agreement with the current literature, and because cells were allowed to differentiate and 
not kept in a proliferation media the percentage of stem and progenitor cells should 
decrease the longer the cells are kept in culture.  Depending on the culturing conditions 
(media, growth factors, etc...) the cells can be directed to keep proliferating or to 
differentiate towards specific phenotypes.
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Table 3.1 Phenotype of HUCB Cells at 1 to 14 DIV 
 
 1 DIV  
2 – 4 DIV 
 
5 – 10 DIV 
 
11 – 14 DIV 
CD45 80 - 90% 90 - 95% 90 - 95% 95 – 99% 
CD34 4 – 5% 1 – 4% < 1% 0 
CD133 1 – 4%      <1 – 2% 0 0 
Table 3.1 HUCB cells immunostaining results for hematopoietic cell markers.  Cord 
blood cells from 5 different donors where used.  The total number of cells and those 
immuno-positive for specific markers were counted and averaged over 80 fields.  Data 
are expressed as the percentage range of phenotypes from donor cells.   
 
 
3.2.3.3   Morphology of HUCB Cells 
In order to evaluate morphology of the HUCB cells, slides were stained with 
Giemsa (Sigma) counterstain to visualize the cell bodies and processes.  After cell were 
prepared and cultured as described above, the cells were in fixed 4% paraformaldehyde 
(pH 7.4) and then thoroughly washed (3 x 10 min each) in 0.1 M phosphate-buffered 
saline (PBS).  Giemsa stain (100 µL) was applied to single wells in the 8-well chamber 
slides for 5 minutes, then rinsed with tap water 3 times, and coverslipped 95% glycerol.  
Figure 3.4 shows cells cultured until day 14 and the five distinct cell types are 
represented.  Cord blood cells started differentiating at 4 DIV and by 14 DIV most of the 
small around cells from days 1-3 had either differentiated or died.  
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Figure 3.4  HUCB Cells Morphology 
 
 
 
 
 Figure 3.4 Photomicrographs demonstrating morphology of HUCB cells.  Cells were 
stained with Giemsa after 14DIV.  The morphology of the cord blood cells shows 5 
distinct cell types which are numbered 1 – 5.  (1) Depicts cells that have a small cell body 
with single long process.  (2) Show cells with large cytoplasm and nucleus.  (3) 
Represent cells with small cytoplasm and multiple processes. (4) These cells are similar 
to 2, but appear to have a smaller cell body and nucleus. (5) These cells appear to be 
forming bipolar cell morphology or they could not yet be fully differentiated. (20x 
objective) 
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  3.2.3.4  Live/Dead Assay of HUCB Cells 
 
 Part of the procedure in characterizing the population of HUCB cells was to 
determine their viability while in culture.  The viability of HUCB cells in suspension was 
determined by a double-labeling procedure using the fluorescein diacetate (FDA, 
Molecular Probes) and propidium iodide (PI, Sigma) method (Zigova & Newman, 2002).  
This method allows identifying the viable, FDA-labeled cells fluorescing bright green 
while dead cells, stained by PI, are bright red.  Cells were periodically assayed 
throughout the 14 DIV.  
 FDA/PI solutions were prepared as follows:  FDA was prepared from stock 
solution of 5 mg of FDA in 1 mL of acetone from which a working dilution of 5 µL of 
stock FDA in 1 mL of 0.1 M phosphate buffer was made prior to staining.  PI stock 
solution was 1 mg of PI in 50 mL of 0.1 M phosphate buffer (kept refrigerated).  FDA/PI 
solution was made be adding 100 µL of working FDA stock solution to 30 µL of PI stock 
solution, which is enough to cover the bottom of one well in the 8-well chamber slides.  
Solution was made from stock as needed.  Media from the well was removed and FDA/PI 
pipetted on top of the cells.  Chamber slides were then placed in the refrigerator for about 
5 minutes.  Cells were counted under dual fluorescent filter (FITC and rhodamine) and 
living (green) and dead (red) cells were visualized (Figure 3.5).  The FDA/PI live/dead 
assays showed that the HUCB cells, in our hands, could be maintained in culture.  In 
addition, the initial viability and cell seeding density of the cord blood cells influenced 
their long-term viability.  The cells have better long-term viability when initial viability is 
high (75% or greater) and with seeding density of at least 106/cm2 or greater. 
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 Figure 3.5  FDA/PI Viability of HUCB Cells 
  
Figure 3.5 Fluorescent photomicrographs of HUCB cells immunolabeled with FDA/PI .  
However, the photomicrograph has been changed to black and white: * denotes red cells 
that are dead; all other cells are alive (stained green). (A, B, & C) Demonstrates that the 
initial sample viability and cell number are critical to the long-term cultures of these 
cells. (A) Cells at 1 DIV show high viability of sample. (B) Photomicrograph of HUCB 
cell at 14 DIV shows low viability. At time of plating, this sample had low cell number 
and viability (64%). (C) Photomicrograph of HUCB cells at 14 DIV shows high viability 
(all green cells) and at time of plating the cell number and viability (96%) was high.  In 
this photograph the bottom layer of cells are adherent to the plate and differentiated, 
while the top layer of cell are small, floating and have not differentiated. (10x objective) 
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  3.2.3.5  Proliferation Assay of HUCB Cells 
 To determine whether HUCB cells proliferate in culture, bromodeoxyuridine 
(BrdU), a thymidine analog, that is incorporated during the S (synthetic)-phase of the cell 
cycle (Gratzner, 1982) was used.  An antibody against BrdU was used to detect the cells 
that have incorporated this analog.  HUCB contains a heterogeneous population of cells 
in which there are approximately 4% stem/progenitor cells that are positive for CD34, 
and less than 1% positive CD133 (Cohen, Gluckman, Rubinstein, & Madrigal, 2000).  
This is in agreement with our results in Table 3.1.  The ability to expand these cells in 
culture could be of importance in the cell transplantation field, especially if more cells 
from one donor are needed due to its unique properties, such as, its HLA antigens.  This 
assay will help determine whether there are stem/progenitor cells that can be expanded in 
culture.  
 HUCB cells were prepared as describe above except they were plated in 96-well 
plates at a seeding density of either 1 or 2 x 106 per well.  Cells were exposed to BrdU (10 
µM) in DMEM cell culture media at 6, 24, or 48 hours before fixing the cells to detect 
BrdU labeling.  Controls used were DMEM and cells plated 1 hour before fixation at the 
initial seeding densities but not exposed to BrdU.  Figure 3.6 shows the proliferation of 
cord blood cells throughout the 48-hour period.  Samples and controls were ran in 
triplicate.  BrdU assay was performed according to the manufacturer’s instruction 
(Chemicon, International) and the number of proliferating cells was determine using a 
microplate reader (BioTek) set to detect luminescence with wavelength of 450/550 nm.  
Results showed that HUCB cell in these culture conditions do proliferate and that higher 
concentrations of cells at plating will increase the rate of proliferation.
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 Figure 3.6  Proliferation of HUCB Cells in Culture 
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Figure 3.6 BrdU labeled HUCB Cells.  Cord blood cells were pulsed at 6, 24, and 48 
hours.  Cells proliferated in culture at both seeding density.  The results suggest the cord 
blood cells can be grown and expanded in culture and that higher seeding densities result 
in an increased rate of proliferation. * Shows significantly more cells in these conditions 
compared to either control cells conditions. (Student’s T-test, p < 0.05). 
 
  
3.2.4 Tool to Measure Migrated HUCB Cells and Control Selection 
 Several initial steps were taken in order to ensure a reliable and verifiable 
migration assay.  The primary step was to establish a way to quantify the number of 
migrating cells without relying on manual cell counting, as this technique is highly 
subjective.  Initially the HUCB cells were labeled with calcein AM (Invitrogen), which 
fluorescently labels the cell bodies and appears red to orange in color.  Figure 3.7 show 
the cord blood cell migrating through the membrane.  While the calcein AM labeled all 
BrdU Pulsing  
100,000cells/well 0.125 
Assay Control 
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Control Cells
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6 Hrs
1687 
24 Hrs 
3464
48 Hrs
1920 2230 5346 4149-0.25 200,000cells/well 
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 cells, there was a large amount of fluorescent background, which interfered when cell 
plates were read in the automatic plate reader (BioTek).  The measurements were not 
reliable, which was noticeable in the standard curves.   The same was true for cholera 
toxin subunit B conjugated to FITC (Alexa Fluor 488, Molecular Probes).  While it 
labeled the nucleus of cells very well, either the background was high or because the 
plate was clear, the fluorescence marker was interfering with neighboring wells.  Hoechst 
33342, DAPI, fluorescent ester dye labeled the cells nucleus, however, many of the cells, 
presumably the stem and progenitor cells, exocytosed the dye very quickly (Figure 3.8). 
 
Figure 3.7  HUCB Cells Migrating through Membrane 
 
 
Figure 3.7 HUCB cells migrating through the top wel
membrane to neonatal rat brain tissue extract. (A
Photomicrograph taken under bright-field showing pores o
membrane (dark round shapes) and migrating cells * (white
irregular shapes).  (B) Fluorescent photomicrograph of same
membrane.  HUCB cells were pre-labeled with calcein AM
white * denotes cells (5 µM solution in 1 mL of media). (20x
objective) 
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Figure 3.8  HUCB Cells Labeled with DAPI 
 
 
 
Figure 3.8 Photomicrographs of HUCB cells in culture at 1DIV. (A) Cells labeled with 
DAPI (Hoechst 33342) fluoresced blue under the DAPI filter, but are depicted here in 
black and white.  (B) Same field taken under bright-field optics.  Note not all cells are 
labeled with DAPI (10x objective).  
 
 Because of the high background in the fluorescent labels, a chemoluminescent 
cell viability assay kit (CellTiter-Glo, Promega) was tried.  This assay determines the 
number of viable cells based on the presence of adenosine 5’ triphosphate (ATP), which 
is present in metabolically active cells.  The luminescent signal is produced by a 
luciferase reaction and the amount of ATP expressed is proportional to the number of 
viable cells in the culture.  The results from the replication of three standard curves using 
HUCB cells are shown in Figure 3.9.  
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 Figure 3.9 Luminescent Standard Curve of HUCB Cells  
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Figure 3.9 HUCB cells were assayed after migration using a luminescent cell viability kit 
(Celltiter-Glo, Promega).  Standard curves were established for each assay and for determining 
sensitivity of the plate reader (BioTech, Inc.).  For standard curves, a serial dilution of cells, at a 
concentration running from 0 to 80,000 cells/300 µL of media, was performed in quadruplicate, 
and pipetted directly into the bottom well of a 96-well plate. RLUs = relative light units.  Graph 
shows the mean of three standard curves for HUCB cells. 
 
The luminescent signal is proportional to the amount of ATP present, which is 
directly proportional to the number of live cells present. The graph contains the mean 
data points of three standard curves.  The results from the standard curves and from initial 
studies proved the CellTiter-Glo cell viability assay to be very reliable and accurate each 
time.   
78 
 In addition to finding a reliable tool to measure the cells that had migrated, there 
was need for a positive control.  The known chemoattractant Stromal Derived Factor –1 
(SDF-1) was chosen and both time and dose response curve were determined.  SDF-1 is a 
strong chemoattractant for CD34+ cells from cord blood and bone marrow.  The optimal 
dose of SDF-1 to induce migration in HUCB cells was 100 ng/mL and optimal time was 
between 4 and 6 hours after which there were no significant increase in the number of 
cells migrating (data not shown).  Additional controls used in migration assay were the 
cell culture media DMEM and PBS.  Both served as negative controls.  
 3.2.5 Protein Assays for Tissue Extracts and Media from HUCB Cells 
 Bicinchoninic acid (BCA) protein assays (Promega, Madison, WI) were used to 
determine the total amount of protein in the tissue extracts for each condition and for both 
the positive and negative controls used in the migration assay.  Protein assays were 
performed twice and each unknown (tissue extracts and controls) or standard were ran in 
triplicate (three wells per assay for 6 data points) according to the manufacturer’s 
instructions.  The standard curves were performed in the same 96 well plate and the assay 
had a working range of 20 to 2,000 µg/mL of protein.  The plates were read in an 
automated plate reader (Synergy, BioTek, Winooske, VT) set to absorbance with 
wavelength of 562 nm.  After measuring the protein concentration for tissue extracts, the 
extracts were standardized to 500 µg/mL for use in migration, cytokine, and ELISA 
assays.  Figure 3.10 represent the mean of 3 standard protein curves.  
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Figure 3.10  Standard Curve for Protein Assays 
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Figure 3.10 BCA protein assay standard curve.  The standards were performed by serial 
dilution, ran in triplicate, and according to manufacturer’s instructions (Promega).  The 
diluent for the standards was clear DMEM, which was the same dilute for the tissue 
extracts used in all migration assays. 
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 3.3  Migration of HUCB Cells and Animal Models of Disease or Injury 
 
 
In this section, the migration of HUCB cells to neonatal rat brain, the 6-OHDA rat 
model of Parkinson’s Disease (PD), and Sanfilippo mouse model are presented along 
with the methods and materials used.  The stroke model is presented in Chapter 4.  The 
disease or injury models that were used in this study were based on the prevalence and 
impact they have in the general population of the U.S., and our expertise in performing 
these experiments.   
 3.3.1 Basic Migration Assay Procedure 
The following methods were used for all migration assays.  HUCB cells were 
prepared as described in section 3.2.3.1, except they were plated in low adherence 6-well 
culture dishes (Corning, Corning, NY) for 24 hrs in a water jacket incubator set at 370C 
and with 5% CO2, which allowed cells to adjust to the environment before beginning the 
migration assay.  After 24 hrs cells were lifted by gentle pippetting, placed in a 15 mL 
tube, centrifuged, resuspended in 1 mL of media, and viability was assessed using the 
trypan blue dye exclusion method.  Only HUCB cells with 80% or greater viability were 
used and cell concentration was adjusted to 62,000 cells/25 µL of media.   
 The basic procedures for the migration assay in all models are similar.  The main 
difference in the procedures between models was the selection of brain tissue to use.  The 
assay uses a 96-well chamber plate consisting of bottom wells that hold the samples or 
chemical attractants and a top plate, which is a polycarbonate membrane with 5 µm pore 
size and is where the cells are placed.  Tissue extracts (300 µL) were pipetted into the 
bottom wells of the 96-well plates.  The top plate was placed on top of the bottom well 
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 plate and HUCB cells were directly pipetted into the top well at a concentration of 62,000 
cells per 25 µL.  The migration chambers were then placed in a water-jacket incubator at 
37°C with 5% CO2 for 4 hours.  SDF-1 was used for positive control and DMEM used as 
negative control.  For each assay sample, control and standard were performed in 
triplicate.  After 4 hours, the top well plates were removed.  The bottom plates were then 
centrifuged; half the media (150 µL) was removed, and Celltiter-Glo cell viability assay 
was performed (according to manufacturer’s instructions).  The plates were then read in 
an automatic plate reader (BioTek) set to luminescence to determine the number of cells 
that migrated into the lower chamber.  In all migration studies, the plate reader was set to 
a sensitivity of 100.  
3.3.2 Preparation of Tissue Extracts 
Animals were sacrificed by exposure to CO2.  Brains were removed within two 
minutes, immediately frozen on dry ice and then stored at –800C until needed.  The 
frozen brains were semi-thawed, kept cold, and the brain areas of interest were dissected 
from both hemispheres.  Tissue from each of the conditions were pooled, and kept on ice 
in clear DMEM.  The preliminary findings showed that fetal bovine serum attracts HUCB 
cells, therefore this was not added to the homogenate media (data not shown). Tissue was 
homogenized at 150 mg of tissue per 1mL of media.  The homogenates were centrifuged 
(400g for 20 minutes), the tissue extracts (supernatant) collected, filtered (0.22 µm, 
Millipore, Bedford, MA), and stored at -800C  until used. 
 
 
 
82 
 3.3.3 Animal Models Used for HUCB Cell Migration 
 The three animal models that follow used the same methods and materials 
described above.  The unique methods or materials that are relevant to each model is 
discussed along with a brief background for each model, which has been incorporated to 
provide the reader with the necessary information to comprehend the premise of the 
animal models selected.   
 3.3.3.1  Neonatal Young Rat Model 
 Cell migration is an essential component of embryonic development as mentioned 
in Chapter 2.  During embryonic genesis in central nervous system, there is a tremendous 
amount of stem cell proliferation, migration, and differentiation.  Stem cells reside, 
proliferate, and migrate from two germinal matrices.  The neuroepithelium (also called 
ventricular zone and ependymal layer) is the primary source of neurons and is derived 
from the neuroectoderm of the neural plate.  The second germinal matrices consist of the 
subventricular zone (which is close to the ventricle) and the external germinal/granular 
layer (Boulder Committee, 1969).  Stem cells in this region give rise to mostly granular 
cells.  The neuroblast cells (precursors of neurons) migrate away from the matrices in 
several manners.  They will migrate in both short and long distances in various directions 
and go through dense brain tissues and over the surface of the brain.  Once the cells reach 
their destination, they stop proliferating and differentiate (Altman & Bayer, 1995).   
The stem cell proliferation, differentiation, and migration are regulated by a strict 
timetable.  Neurogenesis is known to continue into the postnatal period, mainly in the 
external granular layer with respect to the cerebellar cortex and the dentate gyrus of the 
hippocampus (Altman & Bayer, 1995; Peretto, Merighi, Fasolo, & Bonfanti, 1999). 
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 In the rat, the CNS in not fully developed until at least postnatal day 14 (Clancy, 
Darlington, & Finlay, 2001), which enables the study of stem cells’ attraction to the 
embryonic and postnatal brain across a developmental period.  In addition, cell 
transplantation studies in the developing rodent brain have shown that this environment 
supports the survival and migration of embryonic human neural stem cells (Flax et al., 
1998), neuronal restricted precursors (Yang et al., 2000), as well as less differentiated 
progenitor cells derived from the neonatal subventricular zone (Brustle et al., 1998; 
Zigova et al., 1996).  Following transplantation into germinal matrices/zones embryonic 
stem cells were able to participate in normal development including migration along 
established migratory routes and to differentiate into site-specific cell types.  Also, 
studies have reported that the rodent adult brain can support the transplantation of 
subventricular zone derived human embryonic progenitor cells (Fricker et al., 1999; Lois 
& Alvarez-Buylla, 1993).  These findings suggest that the developing brain is a favorable 
environment for studying stem cell proliferation and migration.  Therefore, the neonatal 
rat brain was used to investigate the migration of HUCB cells to these tissue extracts 
(Figure 3.11). 
Neonatal Sprague-Dawely rat pups (male and female) were sacrificed 
(anesthetized with Equithesin, 3.5 mL/kg and heads decapitated) at postnatal days 2 and 7 
(n = 10 per condition). The cerebellum and brain stem were dissected from the brain and 
both the cerebellum and whole brain were used for the tissue extracts from the 2 day old 
rat pups.  The cortex, hippocampus, midbrain and cerebellum were dissected from 7 day 
old rats.   Tissue was prepared as described above.   
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Figure 3.11  Migration of HUCB Cells to Neonatal Rat Brain 
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Figure 3.11 The bar graph represents the migration of HUCB cells to neonatal rat brain 
tissue extracts.  Tissue extracts from 2 and 7 day old rat pups were used.  The CellTiter-
Glo luminescent viability assay kit was used to measure the amount of ATP expressed in 
live cells.  The luminescent signal is proportional to the amount of ATP present, which is 
directly proportional to the number of live cells present.  In all brain tissue extract 
conditions (*) significantly more cord blood cells migrated to these conditions when 
compared to controls (media DMEM).  The 2 day brain and 7 day hippocampus 
conditions had (**) significantly more HUCB cells that migrated than the other extracts 
conditions and more than the positive control SDF-1. [ANOVA One-way between 
groups: F = 2.42, df = 7, 31 with p < 0.0001 followed by planned comparisons using 
Dunn’s Bonferroni (corrected) test with p < 0.05].  
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  The results from this experiment showed that the neonatal brain extracts strongly 
attracts HUCB cells.  Most striking were the 2 day old brain and the 7 day hippocampal 
tissue extracts, which had significantly more cord blood cells migrating compare to the 
other extract conditions.  The results suggest that there are areas within the neonatal brain 
that contain signals, chemoattractants, to induce HUCB cells to migrate.  Because the 
brain is still developing at this time and numerous migration signals are present this 
model was chosen to be the first.  This allowed the techniques and procedures to be 
determined before performing the migration assay on injured or disease models. 
3.3.3.2  Parkinson’s Disease – 6-OHDA Rat Model 
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Parkinson’s Disease is a widespread neurodegenerative disorder first described by 
James Parkinson in 1817 (Parkinson, 1817) and is characterized by a gradual 
degeneration of the dopamine (DA) nigrostriatal system.  Approximately 40,000 people 
in the United Stated are diagnosed with PD every day, and over 1 million Americans 
have this disease.  The daily cost is approximately $66 million that include direct and 
indirect costs such as loss of earnings due to inability to work, social security, medical 
care, and long term care (PDF, 2005).  Symptoms start to appear when at least 50% of the 
dopamine (DA) producing neurons in the substantia nigra are lost, which produces a 70 –
80% reduction in the DA content of the caudate and putamen. The most widely used 
treatment is L-dopa, a DA precursor that crosses the blood brain barrier.  L-dopa 
improves symptoms of PD, but this is not a cure and effectiveness is diminished after 
long period of administration (C. R. Freed, Breeze, & Fahn, 2000; W. J. Freed, 2000).  
The transplantation of human embryonic ventral mesencephalic (VM) tissue has had 
encouraging results in patients with PD (Isacson, van Horne, Schumacher, & Brownell, 
 2001; Olanow, Kordower, & Freeman, 1996; Piccini et al., 1999).  However, there are 
some critical limitations with the use of fetal donor tissue. Only a small percentage of 
VM cells are dopaminergic (<10%) and of that only 1–5% will survive transplantation, 
therefore, up to 15 fetal VM may be required per patient (Isacson, Bjorklund, & Pernaute, 
2001).  Perhaps concerns that are more critical are the ethical and availability issues of 
not only fetal VM tissue but also any other fetal derived cell (stem and progenitor).  In 
light of this, HUCB cells may be one possible alternative to the use of fetal tissue/cells.   
 The 6-OHDA experimental model is one of the most commonly used in PD 
research.  6-OHDA is a neurotoxin that hydroxylates analogues of the endogenous 
neurotransmitter dopamine resulting in nigral degeneration both in vitro and in vivo (for 
review see - (Blum et al., 2001; Blum, Torch, Nissou, Benabid, & Verna, 2000).  Senoh 
and colleagues (1959) were the first to report its isolation (Senoh, Creveling, Udenfriend, 
& Witkop, 1959; Senoh, Witkop, Creveling, & Udenfriend, 1959), and then later Porter 
and colleagues (1963) showed that 6-OHDA depleted noradrenaline in the heart (Porter, 
Totaro, & Stone, 1963).  The presence of this neurotoxin has been reported in the human 
and rat brain, suggesting it may be an endogenous substance (Curtis & Johnston, 1974).  
6-OHDA is typically injected unilaterally into the striatum, substantia nigra or the 
ascending medial forebrain bundle, because it cannot cross the blood brain barrier.  This 
induces asymmetric degeneration of the substantia nigra pars compacta and quantifiable 
motor behavior after administration of DA receptor agonists.   
 Several populations of cells have been experimentally transplanted into the PD 
animal model, with some success.  One of the more interesting was the use embryonic 
stem cells, which were reported to proliferate and differentiate into DA neurons within 
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 the striatum (Bjorklund et al., 2002).  Another study using the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model of PD demonstrated that the intrastriatal 
transplantation of bone marrow stromal cells did improve behavioral deficits seen in mice 
(Y. Li et al., 2001).  Both pre-clinical and clinical studies have shown that certain stem 
cells migrate to the degenerative PD brain.  Therefore, it seemed probable that HUCB 
cells would migrate toward 6-OHDA lesion brain extracts.  However, it was also 
probable that 6-OHDA toxin would inhibit cell migration.  The results are presented in 
Figure 3.12.  Additionally, the migration of HUCB cells to 6-OHDA lesioned brain 
extracts are presented in Figure 3.13.  
 In this experiment adult male Sprague-Dawley rats were lesioned with 6-OHDA.  
The rats (n = 10) were anesthetized with Equithesin (3.5 mL/kg) and unilateral injections 
of 6-OHDA (Sigma; 2.5 µL, 3.6 µg/µL in 2% ascorbic acid in saline) was made at 4.4 
mm posterior to bregma, -1.2 mm laterally and –7.8 mm ventral to dura with the toothbar 
set at –2.4 mm and delivered at a rate of 1 µL/min.  Five minutes after each injection the 
needle was slowly withdrawn and incision sutured.  Other rats (n = 10) received sham 
injection (2% ascorbic acid in saline).  Animals were sacrificed 3 weeks after 6-OHDA 
lesion or sham surgery.  Tissue extract preparation was performed as describe above, 
except that the left and right substantia nigra and the striatum were dissected.  The 
preparation of the cord blood cells and migration assay methods were identical to those 
described above.  
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Figure 3.12 Migration of HUCB Cells to 6-OHDA Toxin and SDF-1 
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Figure 3.12 Migration of HUCB cells to the toxin 6-OHDA and to the chemoattractant 
SDF-1.  6-OHDA had an inhibitory effect of the migration of these cells in a dose 
dependent manner.  The opposite was seen with SDF-1 in which cord blood cells 
significantly migrated to this chemoattractant in a dose dependent manner.  All 
conditions of SDF-1 induced (*) significantly more cells to migrate compared to all other 
conditions.  6-OHDA was not different from controls. The CellTiter-Glo luminescent 
viability assay kit was used to measure the amount of ATP expressed in live cells.  The 
luminescent signal is proportional to the amount of ATP present, which is directly 
proportional to the number of live cells present.  [ANOVA One-way between groups: F = 
2.30, df = 8, 35 with p < 0.0001 followed by planned comparisons using Dunn’s 
Bonferroni (corrected) test with p < 0.05] 
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Figure 3.13 Migration of HUCB Cells to 6-OHDA Animal Model of PD 
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Figure 3.13  Migration of HUCB cells to tissue extracts from rat 6-OHDA model of PD.  
Sham is equal to sham surgery and injected with vehicle instead of 6-OHDA and 6-
OHDA PD equal lesion animals that have been injected with 6-OHDA.  Tissue extracts 
from the substantia nigra and the striatum of unilateral 6-OHDA lesion brains showed 
significantly more migration of HUCB cells compared to the controls and their respective 
sham surgery conditions. * Significantly different from sham surgery and from plain 
media and PBS controls.  [ANOVA One-way between groups: F = 2.38, df = 5, 59 with p 
< 0.0001 followed by planned comparisons using Dunn’s Bonferroni (corrected) test with 
p < 0.05] 
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  These results showing migratory behavior of the HUCB cells in this PD model 
suggest that there are endogenous signals generated by pathology that are capable of 
attracting these cells to the area of injury.  The toxin 6-OHDA actually inhibited the cord 
blood cells from migrating (Figure 3.12).  The typical amount of 6-OHDA used in rat 
models of PD ranges between 3 to 10 µg, which is usually dependent on the injection 
site.  In this experiment, the rats received at total of 9 µg.  However, the brains of these 
animals were not taken until 3 weeks after administration of toxin, which should be 
enough time to reduce the amount of 6-OHDA level directly at the site of the lesion.  The 
sham surgery tissue extracts (Figure 3.13) were significantly different from the toxin 6-
OHDA.  This suggests that in addition to the 6-OHDA in the tissue extracts some other 
factor(s) may be inducing the migration of these cells, such as, chemokines or 
neurotrophic factors.   It also seems likely that the trafficking of these mononuclear cells 
to the site of injury in an in vivo animal model of PD would be a function of several 
factors, including blood brain barrier breakdown, chemokines, and inflammatory 
response.   
 3.3.3.3  Sanfilippo Mouse Model 
 Sanfilippo syndrome type B or mucopolysaccharidosis type III (MPS III) is a 
group of hereditary lysosomal storage disorders resulting from a failure to break down 
glycosaminoglycan, heparan sulfate, within lysosomes.  Sanfilippo syndrome or each of 
the four subtypes (A, B, C, and D) is an autosomal recessive disorder caused by the 
deficiency of a different enzyme in the degradative pathway of heparan sulfate: A) 
heparan-N-sulfatase, B) α-N-acetylglucosaminidase (Naglu), C) acetyl-CoA N-
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 acetyltransferase, and D) N-acetylglucosamine-6-sulfatase.  The absence of any one of 
these enzymes leads to undegraded heparan sulfate accumulation in lysosomes and then it 
is excreted in urine.  MPS III is caused by a deficiency of enzyme alpha-N-
acetylglucosaminidas (Naglu), as a result of a mutation on chromosome 17q21 in the 
gene encoding Naglu.  Premature death occurs one hundred percent of the time (usually 
occurs between 11-20 years of age) with devastating clinical abnormalities, severe central 
nervous system involvement and somatic disease.  Sanfilippo syndrome has no cure and 
affects approximately 1 in 25,000 births in the United States (MPS, 2003) 
A knockout mouse model of MPS III B, demonstrating biochemical abnormalities 
similar to the human disease, has been created by disrupting the Naglu gene responsible 
for heparan sulfate degradation (H. H. Li et al., 1999).   In this mouse model, biochemical 
abnormalities have been report to be similar to those in human patients (no Naglu activity 
and accumulation of heparan sulfate in many organs).  As the mouse age’s, pathological 
changes are observed and become more prominent, which include brain disruptions in the 
neurons.  Visible symptoms start to occur at 6 months; these symptoms include 
abdominal distention, weight loss, and distended urinary bladder.  Behaviorally the mice 
are hypoactive when tested in open field (Gografe et al., 2003). 
All animals used in the study were obtained (a gift) from Dr. Svitlana Garbuzova-
Davis’ established colony of Naglu mice, at the University of South Florida, which was 
developed from three heterozygous breeding pairs resulting is strain B6.129S6-
Naglutm1Efn mouse (The Jackson Laboratory, Bar Harbor, Maine).  This was the only 
disease model that was used in the migration studies and there was preliminary data from 
our laboratory (Dr. Garbuzova-Davis) suggesting the HUCB cells (when injected into the 
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 Naglu mice at one month of age) may increase the life span of these animals.  Therefore, 
the migration study would determine whether HUCB cells would migrate to brain areas 
in this animal model.  
Mice [10 Wild Type (WT) and 10 mutant (MT)] were sacrifice near end of life 
(between 1 to 3 days before death, between 11 to 12 months old), which was determined 
by physical examination of known signs that are exhibited by this mouse population.  
Tissue extracts were prepared as describe above and cerebellum and brain stem were 
dissected from brain this area was labeled “whole brain” (WB).   
 The graph (Figure 3.14) represents one of three migration assays that were 
performed for this disease model.  As a result of the nature of these findings, we felt there 
may have been interference with either the protein or some other factor in the tissue 
extracts.  The protein concentration for mutant and wild type mouse extracts ranged from 
1900 to 2100 µg/mL, which is in the high range of the protein assay (working range of 20 
to 2,000 µg/mL). Therefore, two more assays were performed, with further diluted 
extracts, 100 µL or 10 µL of extract diluted with 200 µL or 290 µL of media, 
respectively.  These assays did not show a pattern of migration and were not similar to 
the initial migration assay using extracts that were standardized for protein concentration 
(protein 500 µg/mL) for each condition.  Although the statistical analysis showed 
significantly more cells migrating to the WT cerebellum extract this finding did not 
match with diluted assays findings.  In fact, in the other assays more cells were found 
migrating to the all tissue extract conditions.  Overall, the data for this model is not 
conclusive. 
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Figure 3.14 Migration of HUCB Cells to Sanfilippo Tissue Extracts 
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Figure 3.14 Migration of HUCB cells to Sanfilippo tissue extracts.  The WT stem 
cerebellum extract was the only condition that showed a significant difference from 
media control.  Each unknown (the tissue extracts), standards, and controls were 
performed in triplicate and the migration assay was performed twice for a total of 6 data 
points per condition.  Significance was set at p<0.05.  (Student’s T-test).  WB = whole 
brain, CB = cerebellum and Stem = brain stem. 
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3.4  Summary 
 The results from the preliminary data have shown that HUCB cells (in vitro) will 
survive for an extended period and that they are capable of proliferating.  After testing 
several labeling methods, to determine the number of migrated cells, the CellTiter-Glo 
luminescent assay was determined to be the most reliable method.  HUCB cells were 
shown to be attracted to the neonatal brain extracts from rats. A significant number of 
HUCB cells were shown to migrate to the 2 and 7 day old whole brain tissue extracts and 
to hippocampal extract of 7 day old rats.  This suggests that the developing brain does 
contain chemoattractants that are signals to HUCB cells to migrate.  It may also be that as 
the brain develops the chemoattractant signaling may become more restricted to certain 
brain regions as indicated by the 7th day.   
The 6-OHDA rat model of PD, showed the migration of HUCB cells to the 
substantia nigra and striatum extracts of lesioned rats.  In addition, HUCB cells, in vitro, 
were shown to be inhibited from migrating to the toxin 6-OHDA at doses from 1 to 10 
µL, which suggest that there are endogenous signals generated by pathology of this 
model that are capable of attracting these cells to the area of injury.  This is an intriguing 
possibility and other models of PD should be investigated for a chemoattractant property 
and compared to the 6-OHDA model   
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 The data from the Sanfilippo mouse model was unclear and we could not confirm 
that HUCB cells migrate to tissue extracts from this disease model.   
 The next two chapters present the data on stroke animals, the cytokines produce in 
the ischemic tissue extracts, and the cytokines or chemokines present in condition media 
from HUCB cells in various culturing conditions.  
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Chapter 4 
 
4.0 Stroke Induced Migration of Human Umbilical Cord Blood (HUCB) Cells: 
Time Course and Cytokines  
 
4.1 Abstract 
There is often a significant delay from the onset of ischemia to the time when 
therapy is initiated in stroke patients.  Thus, there is a critical need to extend the 
therapeutic window regardless of the treatment regime.  Previously, we have shown 
significant improvements in the behavioral defects of rats that received HUCB cells 
twenty four-hours after a middle cerebral arterial occlusion (MCAO).  While the delivery 
of HUCB cells at 24 hours was effective, the optimal time to administer these cells has 
not been established.  Thus, this study investigated the migration of HUCB cells to 
ischemic tissue extracts over several time points with an in vitro model.  A forty eight-
hour “window of opportunity” was established for the delivery of HUCB cells to 
ischemic brain.  The migrated HUCB cells formed cell aggregates in the ischemic 
extracts, suggesting cell-to-cell signaling occurs and the expression of 
cytokines/chemokines in the ischemic extracts suggests their participation in HUCB cell 
migration.  The results from this study are promising in that the current 3-hour 
therapeutic window for the treatment of stroke victims, using approved anticoagulant 
treatment, may be extended with the use of cord blood cell therapy with the peak at 48 
hours. 
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 4.2 Introduction 
 
Stroke is a leading cause of disability worldwide and in the United States affects 
approximately 700,000 (~500,000 first and 200,000 recurrent stroke) people annually 
(AHA 2005).  Although, in recent years there has been an increase in stroke survivors, 
there is still a need to develop more effective treatments and rehabilitative therapies that 
will allow fuller recovery than what is presently seen.  The only Food and Drug 
Administration (FDA) approved drug treatment for acute ischemic stroke is the 
thrombolytic tissue-Plasminogen Activator (t-PA), which acts by breaking down the 
blood clot in the vessel, thus allowing the blood to flow through.  However, t-PA must be 
administered within the first three hours after the onset of acute ischemia and the 
effectiveness of t-PA decreases with time (NINDS, 1995).  Unfortunately, approximately 
40% of stroke patients do not reach a medical establishment within the 3-hour treatment 
window, and the possibility of intracranial hemorrhage must be ruled out by CT thus 
furthering the delay in treatment.  Effective treatments with a longer window of 
opportunity that increases survival rate and improves subsequent recovery are desirable.  
This could also lower the cost of on-going and long-term care.   
Our research group, demonstrated that transplanted HUCB cells significantly 
improve behavioral defects in animal models of stroke (J. Chen et al., 2001; Vendrame et 
al., 2004; Willing, Lixian et al., 2003; Willing, Vendrame et al., 2003), spinal cord injury 
(Saporta et al., 2003), and traumatic brain injury (TBI) (Lu et al., 2002).  Further, HUCB 
cells lengthen life span in mouse model of amyotrophic lateral sclerosis (ALS) (Chen & 
Ende, 2000; Garbuzova-Davis et al., 2003).  In addition, others have shown functional 
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 recovery in a mouse stroke model after delivery of CD34+ HUCB cells; this functional 
recovery was accompanied with  neovascularization and neuroangiogenesis at the 
infarcted site (Taguchi et al., 2004).  Thus, the improved behavioral defects in damaged 
CNS animals utilizing HUCB cells is well recognized and has been extensively reviewed 
(Newman, Davis, Borlongan, Emerich, & Sanberg, 2004; Newman, Davis, Kuzmin-
Nichols, & Sanberg, 2003; Newman, Emerich, Borlongan, Davis Sanberg, & Sanberg, 
2004).  However, several factors pertaining to the HUCB cell treatment model of induced 
MCAO in animals require additional investigation.  Some of the most critical factors that 
require further analysis are the dose of HUCB cells required, location site(s) of infusion, 
delivery time of the cells after induction of MCAO and possible cytokine/chemokines 
that may attract cells to the infarct area or produce the improvements seen in behavioral 
deficits.   
Vendrame et al., (2004), studied the number of HUCB cells required in MCAO 
rats, and showed that the HUCB cells dose dependently reduced the infarct volume of 
ischemic rats.  The optimal dose was 107 cells; at this dose, infarct volume was 
11.46+4.13% of the total hemisphere while control rats (media injected) had an infarct 
volume of 33.15+4.29%.  Particularly important to these findings was the observation 
that the number of cells that migrated to the site of injury was far less than the number of 
cells that were administered.  Similar results were also obtained in spinal cord injury 
(Saporta et al., 2003), and TBI models (Lu et al., 2002).  The location in which to 
delivery these cells was addressed in a study by Willing et al., (2003).  They showed that 
intravenous delivery of HUCB cells to stroke rats resulted in significantly enhanced 
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 behavioral improvements compared to intrastriatal injection.  However, the time at which 
to administer these cells has not been addressed until now.  
Typically, HUCB cells have been administered 24 hours after inducing MCAO in 
the rats, and the evolving damage and death of cells, from the ischemic insult have been 
reported to continue up to 21 days post-ischemia (Butler, Kassed, Sanberg, Willing, & 
Pennypacker, 2002).  The loss of blood flow induces an ischemic cascade of events that 
begins within seconds with the accumulation of Na+ in neurons leading to the shortage of 
ATP and general loss of ionic homeostasis.  The immediate and long-term tissue damage 
depends on the total reduction in cerebral blood flow (CBF), the amount of time the 
tissue is ischemic, the presence of residual flow  and the amount of CBF that returns 
(Maxwell, 1999).  In addition to the primary insult, an inflammatory response starts 
within hours and can last for days, which can lead to further damage from pro-
inflammatory cytokines (i.e. tumor necrosis factor-alpha (TNF-α), IL-1β and IL-6, (see - 
Vila et al., 1999), free oxygen radicals, and nitric oxide (Liu et al., 2001).  Therefore, in 
the treatment of stroke there may be on optimal therapeutic window in which to deliver 
HUCB cells that will assist in preventing or reducing the inflammatory insult.  Thus, this 
study systematically addressed the optimal period to administer HUCB cells, by 
determining when enhanced migration of HUCB cells to ischemic tissue extracts is 
observed in vitro.  In addition, the second part of this study addressed the cytokines 
contained within ischemic tissue extracts.  The results will help determine whether a 
critical window of opportunity exists to administer these cells and provide insight into the 
possible chemokines/cytokines involved in ischemia and the migration of HUCB cells to 
the infarct site.
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 4.3 Material and Methods 
 
4.3.1 Animal Care and Handling 
Adult male Sprague-Dawley rats (Harlan) weighing 200 to 300g were used for 
this study (n = 6 per condition for a total of 54 rats).  Animals were housed in pairs in a 
temperature-controlled room (22 + 30 C) with free access to food and water, and kept on a 
12 hour light /dark cycle.  The rats were handled and monitored daily for two weeks 
before MCAO surgery and afterward until they were sacrificed.  All experimental 
procedures were approved by the USF’s Institutional Animal Care and Use Committee 
and comply with the National Institute of Health, Guide for the Care and Use of 
Laboratory Animals. 
4.3.2 Middle Cerebral Artery Occlusion Surgery  
Animals were anesthetized with 5% Isoflurane in 1L O2/min and maintained in 
1.0 to 2.0% Isoflurane in 1L O2/min throughout surgery.  Anesthetized rats were placed 
in a supine position and a neck incision was made to expose the junction between the 
right external and internal carotid arteries.  The right common carotid, external carotid, 
internal carotid, and pterygopalatine arteries were isolated using blunt dissection 
techniques.  The common carotid was dissected free of the vagus nerve.  The external 
carotid artery was permanently tied in two positions rostrally and a cut was made 
between the two sutures.  After clamping the common and internal carotid arteries, a 26-
gauge needle was inserted into the lumen of the external carotid artery and an embolus (a 
nylon filament 40 mm in length) was inserted through the lumen of the internal carotid 
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 artery to the origin of the middle cerebral artery (approximately 25 mm from point of 
entry).  The filament was tied to produce a permanent stroke and the neck incision was 
closed.  Body temperature was kept within normal limits by use of heating pads until the 
rat recovered.  All animals received Baytril 0.5 ml/kg s.c. and Ketofen 5 mg/kg i.m. for 3 
days after surgery and were monitored continuously until sacrificed.  
4.3.2.1  MCAO Behavior Test 
To insure MCAO surgery induced ischemia the Postural Tail-Hang test (also 
known as The Forelimb Akinesia test) was performed on rats anywhere between 3 to 24 
hours after surgical recovery.  Briefly, the rats were held by the base of the tail and the 
positions of the forelimbs were recorded.  Rats in which stroke was induced demonstrated 
a characteristic posture with the left forelimb flexed to their chest and with the right 
forelimb stretched out.  Only the rats that met criteria with complete flexure of the 
forelimb were included in the study. 
4.3.3 Preparation of Brain Tissue Extracts 
Animals were sacrificed by exposure to CO2 at 4, 6, 12, 24, 48, 72 hours or 1 
week after MCAO.  Brains were removed within two minutes, immediately flash-frozen 
and then stored at –800C until needed.  The frozen brains were semi-thawed, kept cold, 
and the striatum, hippocampus, and the cortex were dissected from both the ipsilateral 
and contralateral sides to the occlusion. The same dissections were performed for sham 
surgery and normal rats. Tissue from each of the conditions were pooled, and kept on ice 
in clear Dulbecco’s modified Eagle’s medium (DMEM, Invitorgen, Carlsbad).  Tissue 
was homogenized at 150 mg of tissue per 1mL of media.  The homogenates were 
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 centrifuged (4000g for 20 minutes), the tissue extracts (supernatant) collected, filtered 
(0.22 µm, Millipore, Bedford, MA), and stored at -800C until used. 
 
4.3.4 Protein Assay 
Bicinchoninic acid (BCA) protein assays (Promega, Madison, WI) were used to 
determine the total amount of protein in the tissue extracts for each condition and for both 
the positive and negative controls used in the migration assay.  Protein assays were 
performed twice and each unknown (tissue extracts and controls) or standard were ran in 
triplicate (three wells per assay for 6 data points) according to the manufacturer’s 
instructions.  Briefly, 25 µL of tissue extracts or controls were pipetted directly into the 
wells of a 96-well plate, 200 µL of working reagent was added, and the plate was placed 
on a shaker for 30 seconds, covered, and incubated at 370C for 30 minutes.  The standard 
curves were performed in the same 96 well plate and the assay had a working range of 20 
to 2,000 µg/mL of protein.  The plates were read in an automated plate reader (Synergy, 
BioTek, Winooske, VT) set to absorbance with wavelength of 562 nm.  After measuring 
the protein concentration for rat ischemic tissue extracts they were standardized to 500 
µg/mL for use in migration, cytokine, and ELISA assays. 
4.3.5 Preparation of HUCB Cells 
Cryopreserved mononuclear fraction of HUCB cells were obtained from Saneron 
CCEL Therapeutics, Inc.  Cells were thawed and pipetted into 9 mL of media [clear 
DMEM with 5% FBS and 1 µL/1mL of Gentamicin (Sigma, St. Louis)].  Cells were then 
centrifuged at 400 g for 15 minutes, the supernatant was removed, and the cells 
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 resuspended in 1 mL of media.  Cord blood cells were then plated in low adherence 6 
well culture dishes (Corning, Corning, NY) for 24 hrs in a water jacket incubator set at 
370C and with 5% CO2 ..      After 24 hrs cells were lifted by gentle pippetting, placed in a 15 
mL tube, centrifuged, resuspended in 1 mL of media without FBS, and viability assessed 
using the trypan blue dye exclusion method.  Only HUCB cells with 80% or greater 
viability were used and cell concentration was adjusted to 62,000 cells/25 µL of media.   
. 
4.3.6 Migration Assay 
The tissue extracts (supernatant) of each brain area (striatum, hippocampus, and 
cortex) from both the ipsilateral and contralateral sides and for each time period (4, 6, 12, 
24, 48, 72 hours, or 1 week after stroke) were pooled together per condition.  The 96-
Chemotx® Chambers (Neuro Probe, Gaithersburg) were used for these migration assays.  
The chamber is a 96-well plate consisting of bottom wells that hold the unknowns or 
chemoattractant and a top plate, which has a polycarbonate membrane with 5 µm pore 
size.  Either 300 µL of the tissue extracts (unknowns), standards, or controls were 
pipetted into the bottom wells, in triplicate, after which the top plate was securely 
attached to the bottom plate.  The HUCB cells were pipetted directly into the top well at a 
concentration of 62,000 cells per 25 µL.  The migration chambers were then placed in a 
water-jacket incubator at 37°C with 5% CO2 for 4 hours.  The top plates were removed 
and the bottom plates were then centrifuged (300g for 10 minutes) so that all migrating 
cells would be forced to the bottom.  Half the media (150 µL) was then removed and a 
cell viability assay (CellTiter-Glo Kit, Promega), which is based on the incorporation of 
adenosine 5’ triphosphate (ATP) into live cells, was used to determine the number of 
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 cells that had migrated.  The migration plate was read in an automated plate reader 
(BioTek) set to luminescence.   
4.3.6.1  Controls 
Stromal cell-derived factor – 1 (SDF-1, 100 ng/mL, Serologicals, Norcross), a 
chemoattractant known to induce the migration of HUCB CD34+ cells, was used in this 
study as a positive control.  Clear DMEM, which was used as the diluent in the tissue 
extracts and the media used to culture HUCB cells, was used as a negative control in the 
migration and protein assays.   
4.3.6.2  Standard Curves 
Standard curves were established for the migration assays and for determining 
sensitivity of the plate reader.  A serial dilution of cells, at a concentration running from 0 
to 80,000 cells/300 µL of media, was performed in triplicate, and pipetted directly into 
the bottom wells of a 96-well plate.  The CellTiter-Glo cell viability assay was performed 
according to the manufacturer’s instructions.  The amount of ATP expressed was directly 
proportional to the number of cells present in each well.   
4.3.7 Rat Cytokine Array  
The rat cytokine antibody array kit (RayBiotech, Inc) simultaneously profiles’ 19 
cytokines from rat brain tissue extracts.  Array membranes were placed in the tray 
provided 2 mL of blocking buffer was added and incubated for 30 minutes at room 
temperature.  After washing [3 times with 2 mL of Wash Buffer I (provided), then 2 
times with Wash Buffer II (provided) on shaker for 5 minutes], 1 mL of standardized 
striatal tissue extracts (12, 48 hours, 1-week MCAO and non-MCAO extract) was added 
and incubated for 2 hours with the membrane to allow cytokine binding to immobilized 
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 antibodies on the arrays.  Membranes were washed again as described above and 1 mL of 
diluted biotin-conjugated antibodies (4 µL in 996 µL of blocking buffer) was added, 
incubated for 2 hours, and washes were repeated.  After which 2 mL of diluted HRP-
conjugated streptavidin (2 µL in 1998 µL of blocking buffer) were incubated on 
membranes for 60 minutes and washes were repeated and decanted.  Detection buffer 
(500 µL) was placed on the membranes for 5 minutes, membranes were lifted with 
forceps to drain excess buffer, placed on Whatman paper, covered with Saran, exposed to 
x-ray film (1 to 5 minutes) and developed.  
4.3.8 ELISA for Rat GRO/CINC-1 and MCP-1 in Ischemic Tissue Extracts  
Ischemic tissue extracts were prepared as described above.  The striatum, 
hippocampus, and cortex areas in ischemic rats taken at 4, 6, 12, 24, 48, 72 hours and 1 
week after MCAO from the ipsilateral and contralateral sides to the occlusion were used 
in both rat ELISAs.  In the rat GRO/CINC-1 ELISA, 100 µL of ischemic and control 
tissue extracts for each condition were incubated in 96 well micro-plate (unknown and 
standards were performed in triplicate) for 1 hour with immobilized polyclonal antibody 
to rat GRO/CINC-1.  The bound cytokine was incubated with appropriate labeled 
antibody, substrate solutions, and standard curve performed according to manufacturer’s 
instructions (TiterZyme EIA, Assay Designs, Inc.) with a range of 0 - 300 pg/mL.  In the 
rat Monocyte Chemoattractant Protein-1 (MCP-1) ELISA, 50 µL of ischemic and 
controls tissue extracts were incubated in a 96-well plate (each unknown and standards 
were performed in triplicate) for 1 hour with immobilized antibody to rat MCP-1.  Bound 
cytokines were incubated with appropriate labeled antibody, substrate solutions, and 
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 standard curve performed all in accordance to manufacturer’s instructions (Rat MCP-1 
ELISA Kit, Pierce Endogen).  The assay had a range of 0 - 1500 pg/mL.  The amount of 
bound GRO/CINC-1 and MCP-1 were measured in a chemoluminescence reader 
(Synergy, BioTek, Winooske, VT ) set to absorbance at 450nm and 550nm, respectively. 
4.3.9 Statistical Analysis 
Migration assay unknowns (the tissue extracts), standards, and controls were 
performed in triplicate and the migration assay was performed twice for a total of 6 data 
points per condition.  A two-way analysis of variance was used to analyze data for the 
migration assay and significance was set at p<0.05.  Further analyses of planned 
comparisons were performed using Dunn’s Bonferroni (corrected) test.  The same 
analysis was used for the ELISAs, and Student’s t-Tests were used for the rat cytokine 
arrays after using Image Pro Plus software (Media Cybernetics, Inc Silver Spring, MD) to 
determine optical density.   
 
4.4 Results 
 
4.4.1 Migration of HUCB Cell to Ischemic Tissue Extracts 
When we examined the HUCB cells after migration to the ischemic tissue extracts 
from striatal and hippocampal conditions at 24, 48, and 72 hours, we observed the 
formation of cell aggregates which were progressively larger in the later times after 
stroke (Figure 4.1). This migration of the HUCB cells to the stroked tissue extract is 
typical of true chemotaxis (the attraction of cells in a positive gradient).  Aggregates did 
not form in the non-stroke brain areas (contralateral sides).  The positive control, SDF-1, 
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 showed migration of these cells in a random fashion with no cell aggregation or cluster 
formation upon reaching the bottom well, indicative of chemokinesis (migration in a 
random direction).   
Figure 4.1 Migrated HUCB Cells in Striatal Ischemic Tissue Extracts 
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Figure 4.1 Bright-field photomicrographs of HUCB cells that have migrated to MCAO tissues extracts and 
controls.  Pictures were taken of the bottom well in the 96-well plate on an inverted microscope at 10x.  
(A,C,E) Shows the numerous HUCB cells that migrated to striatal and hippocampal extracts at both 24 hr 
and 72 hr after MCAO.  Upon reaching the bottom plate, the cells began to form cell-clusters in these 
conditions.  (B, D, F, H) Very few cells migrated to the control conditions and this was typical for all 
samples tested.  (G) Cells also migrated to this chemoattractant SDF-1, however, the pattern of migration 
was more random with no defined cell clusters. Bar = 100 µm applies to all photomicrographs 
  
 This is the first study to report a time-dependent factor in which the mononuclear 
fraction of HUCB cells migrate to ischemic tissue extracts; the time at which the brains 
of stroked rats are harvested after MCAO directly effects the number of HUCB cells that 
migrate toward brain areas damaged by ischemia (Table 4.1).  Significantly more HUCB 
cells migrated to the ipsilateral striatal extract at 24, 48 and 72 hours after MCAO 
compared to the same area on the contralateral side (p <0.0001) and to media control 
(Figure 4.2.A).  Significantly fewer cells migrated to striatal ipsilateral tissue extracts at 
4, 6, and 12 hours compared to their contralateral control side (p <0.05).  However, by 1 
week there were no significant differences between the tissue extracts of either side.  The 
tissue extracts for the hippocampal area showed similar results as the striatum, at both 48 
and 72 hours (Figure 4.2.B); significantly more HUCB cells migrated to the stroke side 
than to the non-stroke side, media control, and when compared to the stroke side at  4, 6, 
12 hours and 1 week (p <0.0001).  A trend similar to that seen with striatal extracts were 
observed in the earlier time points with fewer HUCB cell migration at 4 and 6 hours to 
the hippocampal ipsilateral tissue extracts when compared to their contralateral side 
(p<0.005).  When we examined the cortex, there were significant main effects for the side 
of the brain and time factors (p <0.0001, Table 4.1) and a side by time interaction 
(p<0.0001).  Upon further analysis, there were only significant differences between the 
stroke and non-stroke cortex extracts at 24 hours and 1 week (Figure 4.2.C).  Fewer cells 
migrated to the cortex stroke brain tissue extract at 24 hours compared to the non-stroke 
side.  Lastly, at 1 week more HUCB cells migrated to the cortex stroke brain tissue 
extract than the non-stroke side.    
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Table 4.1. 
Analysis of Variance for HUCB Cells Migration to Striatum 
 
Source   df F-Ratio  Prob 
         
Striatum  (A)  1 0.35482   0.5333 
Time (B)  6 467.3022  <0.0001 
A X B   6 137.6980  <0.0001 
Within Cell  70 
Total   83 
 
Analysis of Variance for HUCB Cells Migration to Hippocampus 
 
Source   df F-Ratio  Prob 
         
Hippocampus  (A) 1 14.9061  <0.0002 
Time (B)  6 559.209  <0.0001 
A X B   6 178.2521  <0.0001 
Within Cell  70 
Total   83 
Analysis of Variance for HUCB Cells Migration to Cortex 
Source   df F-Ratio  Prob 
         
Cortex (A)  1 32.4057  <0.0001 
Time (B)  6 99.1623  <0.0001 
A X B   6 71.2945  <0.0001 
Within Cell  70 
Total   83 
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Figure 4.2 Migration of HUCB Cells to Stroke Tissue Extracts 
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Figures 4.2  The relative number of HUCB 
cells that migrated to MCAO brain tissue 
extracts at 4, 6, 12, 24, 48, 72 hrs and 1 week 
after ischemia and to controls.   
(A) There was a significant number of HUCB 
cells that migrated to the stroked striatal tissue 
extracts at 24 hours (*) and to the stroked 
striatal and (B) hippocampal tissue extracts at 
48 and 72 hour conditions (*) when compared 
to tissue extracts from non-stroke side or plain 
media. (A) Interestingly, at 4, 6, and 12 hours 
significantly fewer cells (#) migrated to the 
striatal stroke tissue extracts compared to non-
stroked control.  
Controls 
SDF-1   Media 
Figure 4.2 (continued) (B) And at 4 and 6 hours after stroke fewer cells (#) migrated to 
hippocampal stroke tissue extracts compared to non-stroke hippocampal extracts.  (C) At 1 
week (#) more cells migrated to cortex stroke extracts than from cortex non-stroke extracts 
while at 24 hr fewer cells migrated to the stroke side when compared to non-stroke side.  (D) 
Significantly more HUCB cells (**) migrated to SDF-1 chemoattractant and fewer cell 
migrated to the media control (#) compared to all other conditions.  
 4.4.2 Rat Cytokine Array 
 
 The rat cytokine array showed that the cytokine with the most intensity was 
Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) for striatal tissue extracts at 12, 48 
hours and 1 week when compared to non-stroke tissue extracts and control media (Figure 
4.3).   
 
Figure 4.3 Rat Ischemic Extracts Cytokine Array 
 
 
Figure 4.3  Photomicrographs of the rat cytokine 
membrane film. (A,B) Shows cytokines expressed at 12 
hours after ischemia in striatal extracts.  TIMP-1 was more 
intense at 12 and 48 hours and 1 week in striatal ipsilateral 
sides (B, D, and F).  (C and D)  At 48 hours MCP-1 and
CINC-1 were also, elevated compared to control sides.  (E 
and F)  By 1 week CINC-1 and β-NGF were more 
intensely labeled on the stroked side than the non-stroked
side.  (G) DMEM (the media) used for tissue processing,
shows no cytokine expression.  (H) Normal striatal rat 
brain extract had no measurable cytokine expression. 
Student’s T-test was used to test significance (p < 0.05). 
Optical density of stroke conditions (B,D,F) were 
compared to non-stroke conditions (A,C,E). 
 
 
 
In addition, the other cytokines visualized and found significant in order of 
intensity were MCP-1 and Cytokine-induced Neutrophil Chemoattractant-1 (CINC-1) at 
both 48 hours and 1 week, CINC-3 and Nerve Growth Factor-beta (β-NGF) at 1 week 
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 compared to non-stroke tissue extracts and media controls.  Based on these data we chose 
to investigate further Growth-Regulated Oncogene/CINC-1 (GRO-CINC-1) and MCP-1 
using ELISA to determine expression over time after MCAO in rats.  GRO-CINC-1 has 
been reported to be the rat equivalent to human Interleukin 8 (IL-8) (Ramos, Heluy-Neto, 
Ribeiro, Ferreira, & Cunha, 2003).  Even though rats do not produce IL-8 they do 
respond to it.  Mast cells in the HUCB cell population have also been reported to produce 
IL-8.  
 
4.4.3 Rat ELISAs 
Unexpectedly, both GRO/CINC-1 and MCP-1 showed a time-dependent pattern 
that was similar to the time course of cell migration (Figure 4.4 and 4.5).  The striatal 
ischemic tissue extracts had significantly more GRO/CINC-1 at 4, 6, 24, and 48 hours 
compared to non-ischemic striatal extracts at the same time points (Figure 4.4.A).  
Similar results were seen with hippocampal tissue extracts where GRO/CINC-1 
concentrations significantly increased at 4, 12, 48 and 72 hours, while the cortex extracts 
had elevated levels at all time points compared to non-ischemic extracts (Figure 4.4.B).  
By 1 week for striatal and hippocampal ischemic extracts levels of GRO/CINC-1 had 
returned to normal, however the level remain elevated in the cortex extracts.  In sham 
surgery and normal rat brain extracts GRO/CINC-1 were significantly lower than the 
ischemic striatal, hippocampal, and cortex concentrations at all times (Figure 4.4.C and 
D).   
 
 
117 
  
Figure 4.4 Levels of GRO/CINC-1 in Ischemic Extracts 
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Figure 4.4 Continued 
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Figure 4.4  ELISA graph of GRO/CINC-1 in rat ischemic and non-ischemic tissue 
extracts.  (A, B, C) GRO/CINC-1 concentration in ischemic (stroke) rat tissue extracts 
from 4 hours to 1 week.  (*) shows significant difference from controls (non-stroke) at 
corresponding time points. (D) GRO/CINC-1 concentration in striatal extracts from 
sham surgery and normal brain controls.  Presented controls represents the most 
elevated levels from sham and normal brain. 
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 The MCP-1 in ischemic tissue extracts was expressed later then GRO/CINC-1.  In 
striatal ischemic extracts, significant elevations of MCP-1 were shown at 6, 12, 48 and 72 
hours (Figure 4.5.A), while hippocampal ischemic extracts showed increased levels at 12, 
24, 48, and 72 hours (Figure 4.5.B) and the cortex only showed increases in MCP-1 at 6, 
12 hours and 1 week (Figure 4.5.C) compared to non-ischemic tissues.  MCP-1 for sham 
surgery and normal rat brains was extremely lower compared to concentrations observed 
in ischemic conditions (Figure 4.5.D).   
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 Figure 4.4 Levels of MCP-1 in Ischemic Extracts 
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 Figure 4.5 Continued
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Figure 4.5  ELISA graph of MCP-1 in rat ischemic and non-ischemic tissue extracts.  (A, B, C) 
MCP-1 concentration in ischemic rat tissue extracts from 4 hours to 1 week.  (*) shows 
significant difference from control at corresponding time points. (D) MCP-1 concentration from 
sham surgery and normal brain controls. The controls present here represent the most elevated 
levels in all control conditions.  
  
4.5 Discussion 
 
In utilizing an in vitro model of migration, we were able to emulate the actions of 
HUCB cells in the microenvironment of stroke.  The present findings are the first to show 
the aggregation and migration of HUCB cells to ischemic tissues extracts with a time-
dependent factor.  In addition, this is the first report of the levels of GRO/CINC-1 and 
MCP-1 in ischemic extracts at several periods after stroke has occurred.  
Once the HUCB cells migrated to the tissue extracts, cell clusters formed on the 
bottom well with smaller aggregates of cells in the striatal and hippocampal tissue 
extracts at 24 hours, and larger aggregates at 48 and 72 hours.  Although some cells 
migrated to extracts of the contralateral sides, these cells upon reaching the bottom well 
did not form clusters (Figure 4.1) suggesting a random migration.  Even with the SDF-1 
chemoattractant, in which a large number of HUCB cells migrated, no clustered 
formations were observed which is consistent with our previous observation of this 
chemoattractant in vitro.  The aggregation of these cells in the stroke tissue extracts 
suggest that in this microenvironment there is cell-to-cell interaction and signaling, which 
could be mimicking what occurs upon transplantation of these cells in this model of brain 
injury.   
We used the MCAO animal model of stroke in rats to establish the optimal time 
for delivery of these cells for use in transplantation.  This model produces localized CNS 
infarction in which intervention strategies such as neural transplantation can easily be 
evaluated.  The middle cerebral artery receives approximately 80% of the blood passing 
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 through the internal carotid artery.  The MCAO model has been shown to produce 
marked cell damage and neurobehavioral deficits that parallel the ischemic strokes 
observed in humans.  The occlusion of the MCA results in cell damage and/or loss of 
cells in the striatum, hippocampus, and cortex ipsilateral to the occlusion.   
Typically, our laboratory and others have transplanted HUCB cells 24 hours after 
induction of ischemia.  The findings from this study suggest that a later time (48 hours) 
may be a more optimal time to deliver these cells, with more cells migrating to the 
ischemic extract (Figure 4.2) resulting in greater therapeutic benefits.  This is especially 
important when cells are administered intravenously, after which the cells must migrate a 
rather far distance to the site of injury.  However, research by this laboratory and others 
have established the “proof of principle” that intravenous administration of HUCB cells 
results in vast improvement in behavioral deficits in animal models of stroke (Chen et al., 
2001; Taguchi et al., 2004, Willing et al., (2003); Vendrame et al., 2004; Willing, 
Vendrame et al., 2003).  Also, the same has been shown in spinal cord injury (Saporta et 
al., 2003), TBI (Lu et al., 2002), and ALS (Chen & Ende, 2000; Garbuzova-Davis et al., 
2003).  
The observed migration of HUCB cells to extracts from the injured brain is 
consistent with earlier reports (J. Chen et al., 2001; Lu et al., 2002).  Previously, HUCB 
cells have been shown to migrate toward ischemic cerebral tissue extract taken at 24 
hours after stroke while bone marrow cells migrated to cerebral extracts at 6, 24, and 48 
hours after stroke compared to controls (Chen et al., 2001; Chen et al., 2001).  However, 
this is the first study to examine systematically the migration of HUCB cells to selected 
areas affected by MCAO over time in rats.  Together these studies suggest that 
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 endogenous signals generated by the pathology are capable of attracting HUCB cells to 
the area of insult, and migration is dependent on the area of the brain and the time the 
cells are administered after stroke.  The results also suggest that at earlier time points the 
injured tissue may be sending out inhibitory cues that inform the cells of a hostile 
environment.  After the initial insult, both cytokines and chemokines are expressed in a 
complex temporal cascade of events.  The pro-inflammatory cytokines have been 
reported to be released early in response to the loss of blood flow followed by 
excitotoxicity of the cells within the core of the infarct (for review see - (Leker & 
Shohami, 2002).  There is an increase in IL-1β, IL-6, TNF-α, interferon- γ (IFN-γ), and 
transforming growth factor - β (TGF-β 1 & 2) mRNA expression as early as 1 hour after 
stroke (Leker & Shohami, 2002).  Expression of these cytokines peaks between 12 and 24 
hours in permanent focal ischemia as determined by mRNA (Hill et al., 1999).  Resident 
reactive microglia are believed to be one of the sources of these cytokines (Kostulas, 
Pelidou, Kivisakk, Kostulas, & Link, 1999; Leker & Shohami, 2002).  These pro-
inflammatory cytokines may exacerbate neuronal damage (Barone et al., 1997; 
Tarkowski et al., 1995; Yang, Zhao, Davidson, & Betz, 1997) and are known to induce 
neutrophil infiltration possibly by the stimulation of CINC.   
Both IL-8 and CINC belong to CXC family of chemokines and are present in 
ischemic brain.  In the cytokine array and ELISAs we showed that CINCs were present in 
ischemic tissue extracts (Figure 4.3 & 4.4).  In the cytokine array, CINC-1 was observed 
at 48 hours and 1 week, while CINC-3 was weakly observed at 1 week.  In the ELISAs 
although there were peaks at certain time points, GRO/CINC-1 was shown to decrease 
gradually from 4 hours to 1 week in all brain tissue extracts.  CINC-1, GRO/CINC-1 and 
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 IL-8 all serve as proinflammatory agents, attract neutrophils, and serve as the first line of 
defense in inflammation, which may be why GRO/CINC-1 is highly elevated early in the 
ischemic striatal extracts (4hrs.).  This is especially true if the progression of 
degenerating tissue is considered (from the core outwards), which may indicate that 
neutrophils within the HUCB cells are migrating to the core in a progressive manner and 
aid in reducing the infarct size.  Indirect evidence of this has been reported in Vendrame 
et al. (2004) who showed that HUCB cell infusion reduced the volume of the infarct in 
MCAO rats.  In humans, IL-8 indirectly regulates the migration of neutrophils by 
stimulating CINC-1 in mast cells (Ramos et al., 2003), directly attracts 
polymorphonuclear neutrophils (Kostulas et al., 1999), and participates in mediating the 
inflammatory response and the trafficking of leukocytes into the ischemic area.  The 
infiltration of leukocytes to the ischemic area are believed to be aided by intercellular 
adhesion molecule (ICAM), endothelial leukocyte adhesion molecule (Pantoni, Sarti, & 
Inzitari, 1998) and tissue metalloproteinases (MMPs) which are zinc-dependent 
proteolytic enzymes that are known to weaken the blood brain barrier (Crocker, 
Pagenstecher, & Campbell, 2004).  
TIMP-1 was present on cytokine arrays for all ischemic extracts (12hrs, 48hrs, 
and 1wk) and has also been shown in ischemic rats using other methods (Hedrick, Cohen, 
Nielsen, & Davis, 1984; Romanic et al., 2002).  This cytokine is believed to inhibit 
MMPs in diverse conditions such as wound healing, angiogenesis, cancer metastasis, and 
stroke (Crocker et al., 2004).  One role of TIMP-1 is to rebuild or remodel the 
extracellular matrix by the inhibition of MMPs.  We suggest here that TIMP-1 is 
performing a similar function in rebuilding the extracellular matrix that has been 
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 destroyed by MCAO and at a future point may serve as an adjunct therapy, especially 
because TIMP-1 is seen at 1 week, on both the ipsilateral and contralateral side to the 
occlusion (even though the intensity is weaker on the contralateral side of the brain).  
However, the exact function of TIMP-1 in the ischemic brain requires further 
investigation.   
In addition, to GRO/CINC-1 an elevation in MCP-1 was also observed in both the 
rat cytokine array and ELISA.  MCP-1 has previously been shown to increase the 
migration of bone marrow stromal cells to rat cerebral ischemic tissue extracts (Wang, Li, 
Chen, Gautam et al., 2002; Wang, Li, Chen, Chen et al., 2002).  Here MCP-1 
concentration peaked at 48-hours in striatal extract on cytokine arrays, and in striatal and 
hippocampal tissue extracts at 48 and 72-hours in the ELISAs.  This is similar to other 
reported findings for MCP-1 in ischemic tissue (Wang, Li, Chen, Chen et al., 2002).  This 
chemokine strongly attracts monocytes and serves as a potent immunoregulator, which 
would explain why we see more HUCB cells migrating at the 48-hour period than at 
earlier or later times.   
IL-1β, IL-6, and TNF-α participate in mediating the inflammatory response and 
are chemoattractants for leukocytes as well.  Although the exact actions of these 
individual cytokines remains unknown; both TNF-α and IL-1 have been shown to 
increase the infarct size (Barone et al., 1997; Yamasaki et al., 1995), while IL-6 may act 
as both a pro and anti – inflammatory agent (for review see - Benveniste, 1998).  
Furthering our understanding of initial cytokines expression will aid in establishing 
whether they are responsible for inhibiting the migration of HUCB cells at the earlier 
times to ischemic tissue extracts observed in this study.   
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 SDF-1 was used for a positive control in this study as it has been shown to be a 
strong chemoattractant for hematopoietic progenitor cells (CD34+) from HUCB (Kim & 
Broxmeyer, 1998) and for monocytes and lymphocytes.  In addition, CD34+ HUCB cells 
express a higher level of the CXCR4 (SDF-1 receptor) which is believed to aid in their 
ability to home to bone marrow when transplanted (Yong et al., 1999).  In a mouse model 
of MCAO, SDF-1 was reportedly associated with reactive astrocytes, mostly localized 
within the penumbra, and transplanted green fluorescent protein expressing bone marrow 
cells were found in areas highly immunoreactive for SDF-1 thus suggesting a 
chemoattractant role for SDF-1 (Hill et al., 2004).  There is evidence that SDF-1 has a 
broader role by stimulating release of other chemokines, regulating leukocyte trafficking, 
stimulating the renewal of stem cell, and the release of maturing cells from bone marrow 
for continued hematopoiesis (Broxmeyer et al., 1999; Lee et al., 2002; Onai et al., 2000).   
Two studies have reported that SDF-1 selectively induces the chemokine IL-8 
from cord blood-derived human mast cells (Lin, Issekutz, & Marshall, 2000, 2001).  
Therefore, evidence suggests that multiple chemokines are involved in the migration of 
HUCB cells to ischemic tissue extracts and furthermore, it is likely that several factors, 
including blood brain barrier breakdown, inflammatory response, and trophic factor 
production may be involved in the trafficking of these mononuclear cells to the site of 
injury.   
The results from this study showed that 48-hours is the optimal time for the 
migration of HUCB cells to ischemic tissue and suggest that these cells are induced to 
migrate perhaps by MCP-1, IL-8 (GRO/CINC-1) or other chemokines, and once there the 
chemokine(s), or other factors, induce these cells to aggregate.  Further studies of the 
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 intrinsic and extrinsic mechanisms are required to understand the signals involved in the 
migration of cells to the site of injury.  Our research group is currently investigating the 
optimal time of 48-hours to deliver HUCB cells in our in vivo model of MCAO in rats, as 
well as examining the cytokines and chemokines produced by cord blood cells. 
 
In conclusion, these new results suggest that a wider therapeutic window (from 48 
to 72 hours after stroke) may exist for the treatment of stroke victims using cord blood 
cells, compared to the existing 3-hour post stroke t-PA.  This may also decrease mortality 
rate and improve long-term outcomes for patients.   
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Chapter 5 
 
5.0 Cytokines Produced by Cultured Human Umbilical Cord Blood Cells 
 
5.1 Abstract 
The potential therapeutic benefits from Human Umbilical Cord Blood (HUCB) cells 
for the treatment of certain injuries, diseases, and neurodegeneration is becoming 
increasingly recognized.  The utilization of cord blood cells in various animal models, such 
as ischemia/stroke, traumatic brain injury, myocardial infarction, Parkinson’s Disease, and 
Amyotropic Lateral Scelerosis, has resulted in improvements of behavioral deficits and for 
some diseases, prolonged lifespan.  Previously, we reported the migration of HUCB cells to 
ischemic brain tissue extracts is time-dependent, and that expression of certain 
cytokines/chemokines within the ischemic extracts corresponds to this migration pattern.  
However, the mechanism(s) responsible for the functional improvements in the animal 
models and for the migration of these cells to site of injury or tissue extracts are unknown.  
Here we investigated the expression of cytokines/chemokines produced by HUCB cells 
under various experimental conditions in vitro.  Certain cytokines were consistently 
expressed in the majority of experimental conditions, such as interleukin-8, monocyte 
chemoattractant protein-1, and interleukin-1α.  This research provides insight as to the 
possible cytokines from cord blood cells involved in the functional improvements seen in the 
animal models of injury/disease.  
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 5.2 Introduction  
 
The field of cell replacement/repair for the treatment of diseases and injuries, 
especially those of the central nervous system (CNS), is a crucial area of research that 
could eventually benefit millions of people.  In the last 20 years, although tremendous 
progress has been achieved in the cell transplantation field, negative outcomes reported 
from clinical trials along with ethical concerns involving the use of fetal cells or tissue 
and embryonic stem cells have delayed progress in the cell replacement/repair field.  Our 
group, along with others, has turned to other potential cell sources in order to continue 
the progression of this field.  We have been utilizing cells of hematopoietic origin.  The 
most promising has been those from human umbilical cord blood (HUCB).  Theses cells 
have been used extensively in the treatment of various nonmalignant and malignant 
hematopoietic diseases, especially in children, for the last 15 years (for reviews see - (Lu, 
Shen, & Broxmeyer, 1996) (Cohen, Gluckman, Rubinstein, & Madrigal, 2000). 
Functional improvements in behavioral deficits have been confirmed in rats that 
were administered HUCB cells following middle cerebral artery occlusion (MCAO) 
(Chen et al., 2001; Vendrame et al., 2004; Willing, Lixian et al., 2003; Willing, 
Vendrame et al., 2003).  Despite reports that HUCB cells express neural phenotypes both 
in vitro and in vivo (Garbuzova-Davis et al., 2003; Ha et al., 2001; J. R. Sanchez-Ramos, 
2002; J R Sanchez-Ramos et al., 2001; Zigova et al., 2002), few cord blood cells are 
present in the ischemic region when compared to the number of cells injected (Vendrame 
et al., 2004), suggesting that cell replacement is not the responsible mechanism for the 
functional improvements seen.   
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  Previously, we have demonstrated a temporal pattern in the migration of HUCB 
cells to ischemic tissue extracts (Newman et al., In press; Newman et al., 2003).  The 
time at which the rats’ brains were harvested after MCAO proved to be a critical factor in 
the migration of HUCB cells to ischemic brain tissue extracts.  The optimal time after 
stroke proved to be 48 hours. In addition, the striatal ischemic tissue expressed cytokines 
and the chemoattractants, cytokine-induced neutrophil chemoattractant-1 (CINC-1) and 
monocyte chemoattractant protein-1 (MCP-1), at 48 hours after MCAO.  Further analysis 
showed that both growth-regulated oncogene/CINC-1 [GRO/CINC-1, the rat equivalent 
of human interleukin-8 (IL-8)] and MCP-1 from ischemic tissue had time-dependent 
pattern similar to that observed in the migration assays.   
 The mechanism by which HUCB cells induce functional improvements in 
behavioral deficits of MCAO rats remains unknown.  We have suggested previously that 
HUCB cells, once at the infarct, are releasing certain cytokines, chemokines or trophic 
factors that are aiding in the repair and are involved in the functional recovery seen in the 
stroke animal.  Also, the HUCB cells could be releasing signals that attract endogenous 
stem cells to the site of injury, which may further aid in the recovery of the injured 
animals. In this study we sought to identify properties of HUCB cells that may be 
responsible for the therapeutic benefit seen in the rat model of MCAO.  Specifically, we 
have investigated cytokines and chemokines produced by HUCB cells under various 
culture conditions.    
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 5.3 Materials and Methods  
 
5.3.1 Preparation of HUCB Cells 
Cryopreserved mononuclear fractions of HUCB were obtained from Saneron 
CCEL Therapeutics, Inc. (Tampa, FL.).  Frozen samples were thawed either in 10 mL of 
clear DMEM with 5% FBS and Gentamicin (50 µg/mL, Sigma) or with Ex Vivo 10 
media (Cambrex) with Gentamicin (50 µg/mL).  Cells were centrifuged at 400 g for 15 
minutes, the supernatant was removed, and the cells re-suspended in 1 mL of the same 
media.  The viability of all samples ranged from 73 to 95 percent as determined by the 
trypan blue exclusion method.  Cord blood cells were cultured in 5 mL of media in low 
adherence 6 well plates (Costa, Corning) in an incubator set at 370C and with 5% CO2 ...      
Cells were treated in accordance with the protocols for each experiment as described 
below, after which Conditioned Media (CM) (supernatant) was transferred to sterile 
conical tubes by gentle pipetting, and centrifuged at 400 g for 15 minutes to remove any 
remaining cells and stored at -800C.   
5.3.2 Human Cytokine Array Protocol 
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 Human cytokine antibody array kits (RayBiotech, Inc) simultaneously profiled 
either 23 (Array 1.0) or 43 (Array 3.0) active cytokine/chemokine proteins in CM.  Array 
membranes were placed in the provided 6-well tray with 2 mL of blocking buffer and 
incubated for 30 minutes at room temperature. After washing [3 times with 2 mL of 
Wash Buffer I (provided), then 2 times with Wash Buffer II (provided) while on a shaker 
for 5 minutes] 1 mL of CM and control media were added to separate wells and incubated 
for 2 hours with the membrane to allow cytokine binding to immobilized antibodies on 
 the arrays.  Membranes were washed again as described above and 1 mL of diluted 
biotin-conjugated antibodies (4 µL in 996 µL of blocking buffer) was added, incubated 
for 2 hours, and washes were repeated.  Diluted HRP-conjugated streptavidin (2 µL in 
1998 µL of blocking buffer) was incubated on membranes for 60 minutes, washes were 
repeated and the supernatant decanted.  Detection buffer (500 µL) was placed on the 
membranes for 5 minutes, membranes were carefully lifted with forceps to drain excess 
buffer, placed on Whatman paper, covered with Saranwrap, exposed to x-ray film (1 to 5 
minutes) and the film was developed.  In addition to the positive and negative controls on 
each array, we employed cultured media that had not been used to culture the cells as a 
control array, which was used to compare with CM arrays. 
5.3.2.1  Human Cytokine Array Time Response 
Cells from the mononuclear fraction of HUCB (10 million/5mL) were cultured in 
DMEM with 5% FBS and Gentamicin (50 µg/mL) for 4 days.  Media was removed and 
fresh DMEM with no FBS was incubated with the cells for an additional 6 days for a 
total of 10 days or for additional 18 days for a total of 28 days, with media changes 
occurring every 3 days.  The CM and control media were then processed as described 
above and 1 mL of each used in the human cytokine array (Ver. 1.0).  
5.3.2.2  Human Cytokine Array Seeding Density 
Cells from the mononuclear fraction of HUCB were cultured in serum free 
DMEM with Gentamicin (50 µg/mL) for 3 days at concentrations of 5, 10, or 30 million 
cells/5mL of media.  The CM and control media were then processed as described above 
and 1 mL of each used in the human cytokine array (Ver. 1.0). 
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 5.3.2.3  Human Cytokine Array Hematopoietic Media and Stimulants 
HUCB cells (10 million/5mL) were cultured for 1, 5, or 12 days in serum free Ex 
Vivo 10 media with Gentamicin (50 µg/mL).  In addition, cord blood cells (10 
million/5mL) were cultured for 4 days in serum free Ex Vivo-10 media with Gentamicin 
and then media was changed and supplemented with either human Interleukin-3 [5 
ng/mL, (IL-3); BioSource International, Camarillo, CA], thrombopoietin [25 ng/mL, 
(TPO); Chemicon International, Temecula, CA] or no supplementation for an additional 
5 days after which media was changed to plain Ex Vivo-10 for additional 3 days for a 
total of 12 days in culture.  The CM and control media were then processed as described 
above and 1 mL of each used in the human cytokine array (Ver. 3.0). 
5.3.3 ELISA for Human IL-8 and MCP-1 in Culture HUCB Cells 
HUCB cells were cultured for 3 and 7 days in serum free DMEM or Ex Vivo-10 
with Gentamicin (50 µg/mL).  CM was obtained according to the protocol described 
above.  ELISA kits (Endogen, Pierce) were used to measure the amount of human IL-8 
and MCP-1 in CM produced by HUCB cells according to the manufacture instructions. 
Briefly, 50 µL of CM for each condition and controls were pipetted, in triplicate, along 
with serial diluted standards, into a 96-strip well plate, incubated for 1 hour with 
immobilized antibody at room temperature and wells were washed 3 times.  Then 
biotinylated antibody (50 µL) was added, incubated for 1 hour at room temperature, and 
washed 3 times.  Next 100 µL of streptavidin-HRP solution was added to wells incubated 
for 30 minutes and wells washed 3 times.  To allow enzymatic color reaction TMB 
Substrate Solution was added to each well (100 µL) incubated for 30 minutes in the dark, 
stop solution (100 µL) was added incubated for 30 minutes, and ELISA’s plates were 
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 measured in a chemoluminescence reader (Synergy, BioTek, Winooske, VT ) set to 
absorbance at 450nm and 550nm. 
5.3.4 Migration Assays 
 HUCB cells were prepared as described above and cultured for 24 hours before 
use.  The 96-Chemotx® Chambers (Neuro Probe, Gaithersburg) were used for the 
migration assays.  The chamber is a 96-well plate consisting of bottom wells that hold the 
unknowns or chemoattractant and a top plate, which is a polycarbonate membrane with 5 
µm pore size.  The chemoattractants used were human recombinants MCP-1 (5, 10, 20, 
and 30 ng/mL; Endogen, Woburn, MA), IL-3 (1, 5, and 10 ng/mL) TPO (10, 25, and 40 
ng/mL), and Stromal cell-derived factor – 1 [100 ng/mL, positive control (SDF-1); 
Serologicals, Norcross, GA], along with the serum free DMEM and Ex Vivo-10 (300 
µL/well) were pipetted directly into the bottom wells, in triplicate, after which the top 
plate was securely attached.  The HUCB cells were pipetted directly into the top well at a 
concentration of 62,000 cells per 25 µL.  The migration chambers were then placed in a 
cell culture incubator at 37°C with 5% CO2 for 4 hours.  The top plates were removed and 
the bottom plates were then centrifuged (300 g for 10 minutes) so that all migrating cells 
would be forced to the bottom.  Half the media (150 µL) was then removed and a cell 
viability assay (CellTiter-Glo Kit, Promega) based on the incorporation of adenosine 5’ 
triphosphate (ATP) into live cells was used to determine the number of cell that had 
migrated.  The migration plate was read in an automated plate reader (BioTek) set to 
luminescence.   
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 5.3.5 Statistical Analysis 
The membranes used in the cytokines arrays were developed onto x-ray film.  The x-ray 
film was then scanned and the image analysis program, ImagePro-Plus (Version 5.0, 
Media Cybernetics, San Diego, CA) was used to measure optical density.  Higher 
concentrations of cytokines were denser (darker) on the membrane and had a lower 
numeric value, which equated to the optical density.  The measurements were performed 
three times by individual investigators blind to the treatment conditions and interrelator 
reliability was between 85 and 98%.  The three measurements were used in the statistical 
analysis, which was performed using Student’s t-Test with significant set at p<0.05 and 
compare to the control array(s), which was cultured media (no cells).  ELISA’s also 
employed Student’s t-Test to determine significance (p<0.05), and each condition was 
compared to control (DMEM or Ex Vivo-10 media). 
 
5.4 Results 
 
This is the first study to report that the mononuclear fractions of HUCB cells 
produce various cytokines and chemokines in response to culture conditions.  
Interestingly UCB cells in all culture conditions, except for TPO, consistently produced 
two chemokines, IL-8 and MCP-1.  These results support our working hypothesis that 
transplanted HUCB cells release factors that contribute to the recovery of behavioral 
deficits in stroke rats and other injury/disease models, and produce chemokines that may 
be attracting endogenous cells to the area of insult, which are thought to aid in repair and 
recovery.  The most important factors that contributed to the chemokine production were 
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 the amount of time the HUCB cells were in culture and the media and stimulants used.  
The concentration of cells did not contribute to additional cytokine production.  The 
stronger concentration of a cytokine the denser (darker) it appears on the membrane, 
which equates to smaller numeric values on the graphs. 
5.4.1 Human Cytokine Array Time Response: 
Cord blood cells were cultured for a total of either 10 or 28 days in DMEM.  The 
CM from cells that were cultured for the 28 days showed more cytokines compared to the 
10 days condition (Figure 5.1).  All cytokines/chemokines presented in Figure 5.1 were 
significantly different from control.  IL-8 and MCP-1 were  at both times and showed an 
increase in intensity by 28 days.  At 10 days in vitro (DIV) the CM from HUCB cells 
contained epithelial cell-derived neutrophil activating protein (ENA-78), macrophage 
derived chemokine (MDC), onocostation (OSM), and vascular endothelial growth factor 
(VEGF) all of which were not present by 28 days in culture. 
 
However, by day 28 several additional cytokines and chemokines were present: 
IL-6, tumor necrosis factor-α (TNF-α), IL-1α, IL-10, TNF-β, granulocytes-macrophage 
colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), MCP-2, and MCP-3.  
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 Figure 5.1 Cytokines Produced by HUCB Cells 10 and 28 DIV 
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 Figure 5.1. Human cytokines produced by HUCB cells at 10 and 28 days in vitro 
(DIV). Graphs represent the optical density of cytokines in the conditioned media (CM) 
from cultured HUCB cells that were bound to the membrane array.  The higher the 
concentration of bound cytokines to the membrane the denser (darker) it appears, which 
when electronically measured for optical density equates to: the smaller the numeric 
value the greater the concentration of the cytokine.  (A) Cytokines in CM from HUCB 
cells that were culture in DMEM for total of 10 days.  (B) Cytokines in CM from HUCB 
cells that were culture in DMEM for total of 28 days.  (A,B) All cytokines present were 
significantly different from control array (DMEM) and from negative control.  The 
background, negative control and control array were between 90 to 100% identical for 
optical density measures.  All cytokines presented in the graph were significantly 
different from control array (Student’s T-test, p < 0.05). 
 
5.4.2 Human Cytokine Array Seeding Density 
To determine whether the number of cells influenced cytokine production, cord 
blood cells were cultured at increasing concentrations (5, 10, and 30 million cells).  
HUCB cells were cultured for 3 days and the CM from all concentrations expressed the 
same 5 cytokines; IL-8, MCP-1, IL-1α, IL-3, and RANTES, which were all significantly 
denser than control (Figure 5.2.).  There was a significant increase in intensity of these 
cytokine that corresponded to the increase in HUCB cell concentration.    
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Figure 5.2 Effect of Seeding Density on Cytokine Secretion  
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Figure 5.2 Human cytokines produced by HUCB cells at increasing concentration.  Graph 
represents the effect of seeding density on cytokine production in cultured HUCB cells.  
Cells were plated at seeding densities of 5, 10, and 30 million cells/5mL of media 
(DMEM)  for 3 days in vitro (DIV).  Cytokines showed a progressive increase in optical 
density that corresponded to the concentration of HUCB cells plated.  All cytokines 
present were significantly different from control array (DMEM) and from negative 
control.  The background, negative control and control array were between 98 to 100% 
identical for optical density measures.  All cytokines presented in the graph were 
significantly different from control array (Student’s T-test, p < 0.05). 
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 5.4.3 Human Cytokine Array Hematopoietic Media and Stimulants 
To determine whether a serum free media designed to support hematopoietic cells 
or the addition of proliferative agents would induce or inhibit the release of chemokines 
in cord blood cells, they were cultured in hematopoietic media with or without the 
addition of IL-3 or TPO (Figure 5.3 & 5.4).  In Ex Vivo-10 (a serum free media designed 
to support long-term cultures of hematopoietic cells), cord blood cells were induced to 
release the chemoattractant SDF-1, which was not seen in the DMEM conditions.  Again 
IL-8 was the most prominent chemokine released in all Ex Vivo-10 conditions. 
Macrophage colony-stimulating factor (MCSF) was present in the 5 and 12 DIV 
conditions; it was not previously seen in the CM from cells cultured in DMEM (Figure 
5.3 B & C).  In addition, only in the 5 DIV condition was the cytokine Leptin present in 
the CM (Figure 5.3 B).   
Figure 5.3 Effects Hematopoietic Media has on Cytokine Secretion 
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Figure 5.3 Effects that HUCB cells cultured with hematopoietic media has on cytokine 
production.  Cord blood cells were cultured with serum free Ex Vivo-10 media at a 
seeding density of 10 million cells/5 mL for either, (A) 1 DIV, (B) 5 DIV, or (C) 12 DIV.    
(A) Most cytokines in CM from HUCB cells at 1 DIV were not as intense compared to 
same cytokines at 5 DIV (B) or 12 DIV (C).  (B,C) At 5 and 12 DIV is first time SDF-1 
was shown to be present in CM from HUCB cells.  All cytokines presented in the graph 
were significantly different from control array (Student’s T-test, p < 0.05). 
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 When IL-3 was added to the Ex Vivo-10 media a down regulation of several 
cytokines occurred (Figure 5.4 A).  While TPO inhibited MCP-1, it induced the HUCB 
cells to produce transforming growth factor-β (TGF-β) and macrophage inflammatory 
protein-1δ (MIP-1δ), which were not seen in any of the other conditions (Figure 5.4 B).  
 
Figure 5.4 Effects on Cytokines Secretion by IL-3 and TPO  
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 Figure 5.4 Cytokine release after IL-3 and TPO added to hematopoietic media.  HUCB 
cells were cultured for 4 day in serum free Ex Vivo-10, after which cells were cultured 
with fresh media and either (A) IL-3 (5 ng/mL) or (B) TPO (25 ng/mL) for 5 days (with 
media refreshed at 2.5 days).  Cells were then cultured in Ex Vivo-10 for additional 3 
days for a total of 12 DIV.  (A,B) Overall fewer cytokines were present in CM from 
these conditions.  However, the most prevalent cytokine remained IL-8 and surprisingly 
followed by SDF-1 in both conditions.  (B) Although the additions of TPO down 
regulated MCP-1, this condition was the only one to show TGF-β and MIP-1δ in the 
CM.    All cytokines presented in the graph were significantly different from control 
array * (Student’s T-test, p < 0.05). 
 
5.4.4 ELISA results for Human IL-8 and MCP-1 in CM from HUCB Cells 
To investigate further IL-8 and MCP-1 enzyme link immunoassays were 
performed (Figure 5.5 A & B).  In agreement with the cytokine arrays, IL-8 was present 
in CM from both Ex Vivo-10 and DMEM conditions at significantly higher levels than 
controls, however, there were no significant differences seen between 3 and 7 DIV 
conditions or between media conditions (Figure 5.5 A).   
Consistent with the cytokine arrays, there was significantly more MCP-1 in the 
CM from cord blood cells cultured for 3 days with Ex Vivo-10 than in CM from day 7 Ex 
Vivo-10 and day 3 DMEM conditions (Figure 5.5 B).  
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Figure 5.5 ELISA of IL-8 and MCP-1 from CM of HUCB Cells 
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 Figure 5.5 ELISA confirmation of human IL-8 and MCP-1 in CM from HUCB cells.HUCB 
cells at 10 million cells/5 mL were culture in serum free Ex Vivo-10 or DMEM for 3 or 7 DIV. 
(A) IL-8 (pg/mL) was found in all conditions, except controls (media and PBS), and there were 
no significant differences. (B) MCP-1 (pg/mL) was also shown in all conditions, except controls 
(media and PBS), and the CM from 3 DIV Ex Vivo-10 condition contained significantly more 
MPC-1 then at 7 DIV or in the DMEM 3 DIV condition. * (Student’s T-test, p < 0.05).  
 
5.4.5 Migration Assays 
To examine whether MCP-1, IL-3 or TPO were chemoattractants for HUCB cells, 
migration assays were performed.  Previously we have shown that striatal ischemic tissue 
extracts from rats contain MCP-1 and here we show that HUCB cells strongly migrate to 
this extract (Figure 5.).  IL-3 and TPO are often used to maintain long-term cultures and 
for progenitor proliferation.  Therefore, we wanted to determine whether either had 
chemoattractant properties, as well.  Significantly more HUCB cells migrate to MCP-1, 
IL-3 and TPO compared to controls (DMEM and PBS).  However, there were no 
significant differences between the doses used for each protein, which was likely due to 
the closeness in range of the doses employed.   
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 Figure 5.6 Migration Assay  
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Figure 5.6 Migration of HUCB cells to MCP-1, IL-3 and 
TPO.  HUCB cells show a strong chemoattraction to all three 
cytokines/chemokines MCP-1, IL-3 and TPO.  Although a 
dose range for each chemokine was performed there were no 
significant differences between the doses.  A standard curve 
was also performed with the HUCB cells from 0 to 80,000 
cell which corresponded to ATP expression in relative light 
units (RLUs) 0 to 2,500.  * (Student’s T-test, p < 0.05). C1 = 
DMEM, C2 = PBS 
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 5.5 Discussion  
Cytokine arrays, in which multiple cytokines are simultaneously identified (23 to 
43 per membrane), allowed us to obtain “cytokine profiles” of what HUCB cells are 
producing in various culture conditions and at various times.  This study demonstrates the 
significant signal interaction that must be occurring between HUCB cells in order to 
produce this variety cytokines and chemokines and whose profiles change as the culture 
conditions change.   
 IL-8 and MCP-1 are more extensively produced than any other chemokines in the 
human body and have been implicated as the first line of defense in the inflammatory 
reaction.  In this study, both IL-8 and MCP-1 were significantly elevated in the CM of 
HUCB cells under varying culture conditions.  IL-8 was detected in the CM from HUCB 
cells in all culture condition.  Additionally, the intensity of IL-8 was the highest in every 
condition. IL-8 belongs to the super family of cytokines, under the category of 
chemokines, and more specifically is considered an α-chemokine (or chemotactic 
cytokine).  This chemokine is a strong chemoattractant for neutrophils and lymphocytes 
(T-cells), and induces a full pattern of response from these cells, with activation of the 
motile apparatus and directional migration, increase in surface adhesion molecules, 
lysosomal enzyme release, and reactive oxygen intermediates production (Wang, Xu, 
Murphy, Taub, & Chertov, 1996).  We have previously shown an elevated presence of 
IL-8 (Growth-Regulated Oncogene/ Cytokine-induced Neutrophil Chemoattractant-1 
GRO/CINC-1 – rat equivalent of human IL-8) in striatal, hippocampal, and frontal cortex 
of ischemic rat tissue extracts, which was elevated from 24 hours to 72 hours after stroke 
when compare to non-stroked tissues (Newman et al., 2003; Newman, Willing, Manresa, 
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 Davis Sanberg, & Sanberg, 2004).  IL-8 is also elevated in the sera from patients in a 
number of human injuries and diseases, such as, Multiple Sclerosis (Lund et al., 2004), 
coronary heart disease (Qi et al., 2003), traumatic brain injury (Kushi, Saito, Makino, & 
Hayashi, 2003), and ischemic stroke patients {Kostulas, 1999 #6608;Kostulas, 1999 
#6611}.  In addition, IL-8 from cord blood alone or together with other cytokines is being 
used as a determinant for neonatal sepsis (Berner, Tuxen, Clad, Forster, & Brandis, 2000; 
Dollner et al., 2001; Krueger et al., 2001).   
TNF-α and IL-1 have been implicated as the cytokines responsible for stimulating 
the release of IL-8 and MCP-1 (Kasahara, 1991; Kim, 1996; Yang, Hu, Chang, Tai, & 
Leu, 2004) .  However, recently neutrophil chemoattraction to IL-8 was shown to be 
dependent on CINC-1 produced from mast cells (Ramos, Heluy-Neto, Ribeiro, Ferreira, 
& Cunha, 2003).  This discovery may be of importance in the migration of HUCB cells to 
ischemic tissue.  Both neutrophils and mast cells are within the heterogeneous population 
of HUCB cells and depending on the culturing conditions may be maintained for long 
periods (Dvorak, Estrella, Mitsui, & Ishizaka, 1993; Dvorak, Mitsui, & Ishizaka, 1993).  
In addition, ischemic tissue extracts were previously shown to contain significant levels 
of CINC-1 and CINC-3 (Newman et al., In press) and this study has shown the presence 
of IL-8 in every HUCB cell culture condition.  We believe that these converging lines of 
evidence suggest that HUCB cells are partially attracted to ischemic tissue as a result of 
its content of CINC-1, the variety of and interaction of cells within the cord blood 
(including neutrophils and mast cells), and the production of IL-8 from these cells.   
MCP-1 a β-chemokine, was the second most prevalent cytokine present in every 
condition except TPO.  As the name implies MCP-1 is a strong chemoattractant for 
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 monocytes and has a role in the accumulation of monocytes over a 48 hour period after 
interaction of antigen and sensitized lymphocytes (Yoshimura & Ueda, 1996).  However, 
in the Ex Vivo-10 conditions for 1 and 12 DIV, there was a higher level of IL-6 than 
MCP-1, and in IL-3 stimulated condition, both SDF-1 and TNF-α levels were higher than 
MCP-1.  In the brain, MCP-1 is well documented as a major chemoattractant for 
monocytes especially after disease state onset or after injury as part of the inflammatory 
response.  IL-1, TNF-α, IFNγ, and several other stimuli are known to induce the 
expression of MCP-1 from many cell types (for review see - Yoshimura & Ueda, 1996).  
More recently, MCP-1 has been reported to induce the migration of rat-derived neural 
stem cells in vitro (Widera et al., 2004).  Previously, we have shown that the peak 
expression of MCP-1 in ischemic rat brain corresponds to the time when the greatest 
number of HUCB cells migrate to ischemic striatal and hippocampal extracts.  The down 
regulation of MCP-1 seen in the IL-3 condition and more so in the TPO condition may be 
a function of the time at which the CM was taken, which was 12 DIV.  It is possible that 
MCP-1 was expressed at an earlier time in these conditions.  Although IL-1α was present 
in the TPO condition the level of expression was not very strong and TNF-α was not 
present at all in this CM, which suggest cells were not stimulated enough to induce MCP-
1 secretion.  In addition, both IL-3 and TPO are used as a culturing tool to stimulate cell 
proliferation and maturation, and the exposed HUCB cells may have been reacting to 
these cytokines and their microenvironment by down-regulating unnecessary proteins to 
conserve energy for proliferation.   
Interestingly, when HUCB cells were cultured in the hematopoietic media (Ex 
Vivo-10) at 5 and 12 DIV and with IL-3 or TPO, SDF-1 was secreted from the cells, 
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 which was not seen in any conditions using DMEM.  SDF-1 has been shown to induce 
the homing and mobilization of hematopoietic stem cells (HSC), especially to bone 
marrow (Broxmeyer et al., 1999).  Enhanced cell survival (Lee et al., 2002) and the 
potentiation of angiogenesis (Mirshahi et al., 2000; Salvucci, Basik, Yao, Bianchi, & 
Tosato, 2004) has also been shown to be induced by SDF-1.  The chemoattraction of cord 
blood HSC to SDF-1 has been reported as well (Yong et al., 1999).  This chemoattractant 
has been shown to induce IL-8 production in cord blood-derived human mast cells (Lin, 
Issekutz, & Marshall, 2000, 2001).  However, in this study, HUCB cells in cultured 
conditions without SDF-1 also induced IL-8 secretion, which indicates that the presence 
of SDF-1 is not necessary for IL-8 production in cord blood cells.   
Another unique finding was the presence of Leptin, which was induced when 
HUCB cells were cultured in hematopoietic media at 5 DIV.  Leptin is a protein 
predominantly produced by adipocytes and has a role in regulating long-term body 
weight.  Although Leptin has been found in the serum of cord blood and in cells of the 
placenta (Senaris et al., 1997), its function or importance in cultured HUCB cells is 
unknown.   
The amount of time in culture and the media plus the supplements used in culture 
were the major influences in the production of cytokines by the HUCB cells.  The 
cytokine profiles demonstrate the direct reaction of the cord blood cells to their culture 
environment, with cytokines being produced or inhibited in concert with changes in their 
environment.  While these findings give us insight into the ability of HUCB cells to 
produce both cytokines and chemokines, there are remaining questions that need to be 
addressed.  Are selected cells producing only certain cytokines?  If cells are selected 
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 based on a phenotype of interest, will they work independently or is the heterogeneous 
population needed for the correct cell-to-cell interaction?   Lastly, could it be that this 
heterogeneous microenvironment of cells is necessary for the benefits seen in the 
previous transplant studies?     
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Chapter 6 
 
6.0 Relevance of the Dissertation Studies, Conclusions, Limitations, and Future 
Directions  
 
 The main objective of this study was to determine whether HUCB cells had the 
ability to migrate to the injured brain.  The previous transplantation studies in the 
ischemic rat model, which have used these cells, all reported significant functional 
improvements in behavioral deficits (see – Chapter 1).  However, these studies did not 
report a larger number of transplanted cells at the site of injury.  Therefore, we needed to 
determine whether the cord blood cells were attracted to or inhibited from the area of 
injury.  The secondary objectives were to determine, whether there was an optimal time, 
after stroke, in which more cells migrated to ischemic extracts and to identify factors that 
were involved with their migration.  An in vitro model of cell migration and tissue 
extracts from MCAO rat model of stroke were used in this study. 
162 
The results from our preliminary data, which was used to characterize the 
properties of the HUCB cells (in vitro), showed that these cells will survive for an 
extended period and proliferate in culture.  Additionally, these data showed five distinct 
cell types based on morphological visualization, and that the mononuclear fraction of 
cord blood cells are heterogeneous and contains both stem and progenitor cells, which 
was shown by immunophenotyping analysis and their exocytosis of certain nuclear dyes.  
 These results are important especially if the cells are approved to be used in human 
transplantation to repair the injured brain.  The expansion of cord blood cells might be 
necessary if a certain fraction contains unique properties particular for an individual(s) 
(such as their HLA antigens) or if a subpopulation of cells, within the cord blood, are 
determined to have properties exclusive for the repair of a certain brain injury.  Although 
these cells have been used to treat nonmalignant and malignant hematopoietic diseases 
(see – Chapter 1) and more recently cord blood cells have been successfully transplanted 
into infants with Krabbe’s disease (Escolar et al., 2005) and in children with Hurler’s 
syndrome (Staba et al., 2004), they have not been approved for other treatments or for use 
in brain repair.    
In the migration experiments, the HUCB cells were shown to migrate to the 
chemoattractant SDF-1, in a dose dependent manner, 100 ng/mL was the optimal dose 
and 4 hours was the optimal time for migration of the cells.  In the neonatal brain assays, 
HUCB cells migrated to the 2 and 7 day brain extracts and the hippocampal extracts in 
the 7 day condition.  The PD animal model that was studied used the toxin 6-OHDA to 
create a lesion in the rat brain.  The toxin is not the cause of human PD, but does result in 
pathology and symptoms similar to those seen in PD patients.  In the migration assay, 
HUCB cells significantly migrated to tissue extracts from the 6-OHDA lesioned 
substantia nigra and striatum.  In addition, this toxin had an inhibitory effect on the cord 
blood cells, in that the cells did not migrate to the toxin when in solution with media 
only.  The 6-OHDA rat brains were harvested 3 weeks post-lesion, which corresponds to 
the time when lesioned rats have the symptoms and pathology (significant decrease of 
DA neurons and levels) of PD seen in humans.  In addition, 3 weeks post-lesion should 
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 be sufficient time for the toxin to clear or at least appreciably decrease so that it would 
not interfere, to a great extent, with the cell migration.   
More importantly and the primary focus of this study was the MCAO rat model of 
stroke.  HUCB cells were attracted to ischemic tissue extracts in a time dependent 
manner.  More cells migrated to the ischemic extracts that were taken and processed 
between 24 and 72 hours after induction of MCAO in the rat, with the peak migration 
occurring at 48 hours after inducing the stroke.  These results suggested a window of 
opportunity in which to deliver the cells.  A typical protocol for transplantation studies in 
the MCAO model is to administer the cells 24 hours after inducing the stroke.  These 
results showed that 48 hours after stroke might be more optimal for cell transplantation 
studies; we are now examining this in vivo.  Dr. Willing’s group, from our laboratory, has 
been investigating this phenomenon.  Adult male rats received either HUCB cells 48 
hours after MACO or no cells.  The results showed almost full amelioration of behavioral 
and neurophysiological deficits produced by the stroke, and a reduction of the infarct 
volume in MCAO rats.  The results also suggested that the neurons in the core of the 
infarct may not die immediately, and that it is more probable that these cells die slowly 
through apoptotic cell death (Newcomb et al., 2005).  Together the results suggest that 
additional therapeutic strategies, such as anti-inflammatory agents in addition to the 
administration of HUCB cells would increase survival rate and overall recovery.  Most 
importantly, these studies provide strong evidence that the therapeutic window could be 
extended from the current 3 hour treatment and thus allow more stroke victims to be 
treated.   
164 
 The results from the MCAO study also showed an inhibitory effect in the 
migration of HUCB cells to the earlier time points in the ischemic tissues.  Both the 4 and 
6 hours ischemic striatal and hippocampal extracts attracted fewer cells than the 
corresponding contralateral sides, signifying an inhibitory effect.  This effect is possibly 
the result of an increased invasion of pro-inflammatory cytokines (e.g. TNF-α, IL-1β), 
which are known to be released soon after ischemia occurs and peak about 12 hours post-
stroke.   
In studying this model, we also determined some of the cytokine and chemokines 
present in the striatal ischemic tissue extract (see – Chapter 4).  TIMP-1 was the strongest 
expressed cytokine and present in all striatal ischemic extracts assayed and in the 
contralateral side extracts as well.  The TIMPs family has a significant role in rebuilding 
the extracellular matrix that has been damaged during an insult to the brain (Crocker, 
Pagenstecher, & Campbell, 2004).  The strong presence of TIMP-1, in the tissue extracts, 
suggest that in the ischemic brain this protein is performing a similar function probably 
by inhibiting the tissue metalloproteinases (MMPs), which are known to participate in the 
breakdown of extracellular matrix and in weakening the blood brain barrier.  Therefore, it 
is reasonable to assume that TIMP-1 is produced and released by surviving cells around 
the infarct in a response to protect the break down of the BBB extracellular matrix.   
Two known chemoattractants were also strongly present in the ischemic extracts.  
Both MCP-1 and CINC-1 were expressed on the cytokine arrays from the striatal 
ischemic extracts at 48 hours and 1 week.  To help determine whether they had a role in 
the migration of HUCB cells we further investigated their expression in ischemic and 
non-ischemic tissue extracts overtime, by ELISA.  Interestingly, the presence of 
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 GRO/CINC-1 (IL-8) and MCP-1 in the ischemic extracts, over the same time periods as 
the migration studies, showed a pattern that was similar to the results of the migration of 
HUCB cells to the ischemic extracts.  In that both IL-8 and MCP-1, levels were lower in 
the earlier time periods and peaked between 24 to 72 hours, which is when cell migration 
to ischemic extracts was at its peak.   
Our findings are in agreement with the findings of other researchers.  The 
expression of MCP-1 in ischemic brain peaks 2 to 3 days after stroke (Yamagami et al., 
1999); (Che, Ye, Panga, Wu, & Yang, 2001).  MCP-1 may be stimulated by several 
factors, such as, TNF-α, IL-1, IFNγ, LPS, and platelet derived growth factor (PDGF).  
TNF-α, IL-1 and IFNγ are present in ischemic tissues as early as 3 to 6 hours after stroke 
(Kim, 1996) and are key responders to inflammation (Sharma & Kumar, 1998).  In vitro 
studies have shown that TNF-α and IL-1 may induce the production of IL-8 and MCP-1 
from astrocytes (Kim, 1996).  This suggests that these two pro-inflammatory cytokines 
may have a role in chemotaxis.  Both IL-8 and MCP-1 are chemoattractants for 
monocytes, and both were present in the ischemic tissue and in the conditioned media 
from the cord blood cells in culture without any inflammatory agents present.  Although, 
the exact chemokines that induce the cells to migrate remain to be identified, we now 
have insight as to which chemokine families are involved and we believe that more than 
one chemokine is responsible for the attraction of HUCB cells to ischemic tissue.   
A second primary objective of this study was to identify the cytokines and 
chemokines that may be produced by HUCB cells in culture (see – Chapter 5).  The 
amount of time the cells were cultured and the culturing conditions are the two principal 
factors that influenced the cord blood cells secretion of cytokines and chemokines.  The 
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 most prevalent chemokine was IL-8, which was present in every culture condition.  This 
was followed by the presence of MCP-1.  Several other cytokines and chemokines were 
also produced from the cultured HUCB cells.  We postulate that significant cell-to-cell 
signaling (interactions) occurred with the cultured HUCB cells in order for the production 
of such diversity in the cytokines and chemokines.  Further evidence of cell to cell 
signaling is observed in the cytokine profiles, which change as the culturing conditions 
change.  However, within the population of cord blood cells the cells that are producing 
and secreting certain cytokines or chemokines remain to be determined.   
In conclusion, the results suggest that a wider therapeutic window (from 48 to 72 
hours after stroke) may exist for the treatment of stroke victims using cord blood cells, 
when compared to the existing 3-hour post-stroke use of t-PA.  The chemokines that may 
be partially responsible for the migration of HUCB cells were identified (IL-8 and MCP-
1).  The cytokine profiles demonstrated the direct reaction of the cells to their culturing 
environment, with cytokines being produced or inhibited in concert with changes to their 
environment.  This suggests that when cells are administered in the ischemic rat they 
would have the ability to produce cytokines or chemokines that may aid in the repair of 
the injured brain.  An intriguing possibility is that the two most prevalent chemokines 
produces by HUCB cells (IL-8 and MCP-1) may induce the attraction of endogenous 
cells (stem cells) to the site of injury, thus further aiding in the repair of the damaged 
tissue.  Converging lines of evidence, from the transplanted post-stroke animals, the 
migration assays showing an extended therapeutic window (from 3 hours to now 48 
hours), and the production of cytokines and chemokines by HUCB cells, suggest their use 
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 as a treatment for stroke, which may improve the mortality rate and long-term outcomes 
for patients.   
 
6.1 Limitations   
 
In these studies, as with any study, there are the existences of intrinsic limitations.  
Using in vitro cultures and assays is the major limitation in this set of studies.  One major 
problem with in vitro model systems is that they do not necessarily reflect the activity 
that takes places in vivo.  This is especially true with the migration assays that employ a 
chamber, which is an artificial condition that does not contain all the components of the 
in situ environment.  Although this type of design affords the opportunity to examine the 
migration functions in an isolated environment, which has its advantages, it does not 
allow for the complex interactions that undoubtedly occur during the endogenous 
migration of HUCB cells with the surrounding cells, matrix, and the numerous cytokines, 
chemokines or trophic factors that are produced in reaction to ischemia.  The in vitro 
assays allows for isolating the experiment from extraneous variables and may lead to 
significant findings, it is also possible, and must be considered, that false leads could be 
generated.  This problem can be circumvented, to a certain extent, by verifying the in 
vitro results with animal studies, which is currently underway in our laboratory.  
Nonetheless, it must still be appreciated that both the migration assays and the 
cytokines/chemokines produced by cultured HUCB cell systems are an artificial construct 
that can only suggest possible mechanisms that must be explored and the results 
compared to intact animal experiments.   
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 6.2 Future Directions  
 
 Cell transplantation for CNS diseases has always held tremendous medical 
potential.  Chapter 1 discussed the problems associated with fetal or embryonic cells and 
the selection of HUCB cells as an alternative source for cell therapy.  HUCB cells have 
been found to exert pronounced effects when administered systemically in the treatment 
of animals with CNS diseases and injuries as reviewed.   
If the functional benefits of HUCB cells endure scientific scrutiny and with 
appropriate standard pre-clinical safety and toxicological, testing initial Phase I clinical 
evaluation is conceivable in the short term.  The FDA has already approved clinical trials 
using HUCB cells for hematologic malignancies, aplastic anemia, immunodeficiency 
diseases, and metabolic disorders (Thomson et al., 2000; Wagner, Kernan, Steinbuch, 
Broxmeyer, & Gluckman, 1995).  While these clinical trials are not for neurological 
disorders, the level of comfort that regulatory agencies already have with this general 
approach together with the data collected from ongoing trials (related to dosage, GVHD, 
cell survival, safety of the HUCB cells, and their efficacy) will facilitate entry into 
clinical trials for cellular transplantation therapies.  With over 1500 cord blood 
transplants performed worldwide, a strong safety and efficacy database is being compiled 
(Gluckman, 2001; Laughlin et al., 2001)(Gluckman et al., 2001; Laughlin et al., 2001). 
Before HUCB cells, are ready for the clinic, fundamental issues need to be 
addressed.  One of the most obvious issues is the cell type(s) underlying the behavioral 
effects of HUCB injections, which needs to be identified.  HUCB cells are a 
heterogeneous population of cells and have been shown to differentiate into neural cells 
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 both in vitro and in vivo.  While it is tempting to speculate that neural cells are one of the 
essential ingredients for the improved deficits in behavior, this remains an open question.  
The animal transplant studies utilizing cord blood cells thus far are not indicating cell 
replacement as the mechanism for the improvements in the behavioral deficits.  The 
possibility exist that these cells, upon migrating to the injured tissue, are releasing 
cytokines and chemokines that are either directly or indirectly responsible for these 
effects.  Alternative factors, such as these, are being addressed by our laboratory and 
others.  Future studies should systematically isolate the various cell components in 
HUCB and evaluate their therapeutic role in animal models.  These studies should also 
identify effective and non-effective clonal stem cell lines as well as identify methods of 
expanding those lines prior to transplantation.  Serious attention should be paid to 
identifying culturing conditions, media, serum, and other factors to enhance or maintain 
expansion as well as the stage of differentiation of the cells for specific disease 
indications.  
Another issue is the role of the recipient’s immune system after the 
transplantation of HUCB cells.  Grafted HUCB cells (which are considered foreign to the 
host) were shown to have a low rejection rate (see – Chapter 1), but they may also induce 
a low level of chronic inflammatory response that contributes to or minimizes their 
therapeutic potential.  Transplant studies across discordant hosts would provide insight 
into this issue.  Perhaps the observed effect in animals (where a xenograft is being used) 
underestimates the potential in humans.  This is an important point when considering the 
optimization of this or any transplant approach that borrows heavily from pre-clinical 
animal data.  In addition to the host immune response, the role of the host stem cells 
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 should be evaluated.  It is possible that HUCB cells are providing benefits through these 
host cells.  Studies should begin to determine whether grafted HUCB cells stimulate or 
augment the proliferation, migration, and differentiation of endogenous stem cells. 
Refinements in cell labeling coupled with cross-species grafts should be used to 
determine the proportion of host versus donor stem cells within the region of interest. 
Lastly, long-term safety studies along with duration of the behavioral effects and 
survival of the grafted cells should be addressed.  The current studies are relatively short 
term and do not permit determination of any continued improvements, diminishments in 
efficacy over time or overall safety.  These studies should incorporate detailed anatomical 
analysis of cell types within the injured region with particular emphasis on the 
appearance of specific cell types prior to the onset of behavioral improvements and from 
any anatomical abnormalities.   
Certainly, this is only a partial list and we are in the process of fully evaluating 
the effectiveness of HUCB cells in a number of different injury and disease models.  
Despite the need to evaluate further, the issues discussed above, the pre-clinical 
transplantation studies utilizing cord blood cells and the results of theses studies, it is 
reasonable to propose that HUCB cells are a formidable cell source for cellular therapies 
in CNS disorders. 
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